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SUMMARY 
Polyelectrolyte materials based carrier system for controlled release (CR) of 
bioactive proteins and delivery of anti-cancer drugs are of interest to our research due 
to their good biocompatibility and biodegradability. In the first part of this study, 
polyelectrolyte multilayer microcapsules prepared via Layer-by-Layer (LbL) method 
were used for CR of fluorescent bovine serum albumin (BSA). By investigating the 
impact of different loading approaches, shell compositions, and shell thicknesses and 
release environments on BSA release, the shell permeability related protein release 
mechanism was revealed. In the second part, microcapsules prepared by the same 
method were applied in CR of basic fibroblast growth factor (FGF2) and their 
advantages in maintaining the bioactivity of FGF2 and enhancing cell proliferation 
were evaluated in vitro. As the micro-size carrier has drawbacks in intracellular drug 
delivery, in the third part, a polyelectrolyte-TiO2 nanocomposite carrier system was 
developed for anti-cancer drug delivery and through this a surface chemistry related 
synergistic anti-cancer effect was discovered. 
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1.1 Background information 
1.1.1. Definition and existence of polyelectrolyte 
Polyelectrolytes (PELs) are polymers or macromolecules with a certain degree 
of ionic or ionizable groups or both along the main chains or on pendant groups.
1-4
 
Based on the charge of ionizable groups, PEL can be divided into polyanion, 
polycation and polyampholyte which have negatively charged groups, positively 
charged groups and both respectively (Figure 1.1). Based on origin they can be 
categorized as natural occurring, modified natural and synthetic PELs. Proteins, 
polysaccharides, carrageenan, xanthan, gum Arabic and deoxyribonucleic acid (DNA) 
are examples of natural occurring PELs. Modified starch and cellulose sulfate belong 
to modified natural PELs. Polymeric acids such as poly(acrylic acid) (PAA) and 
poly(methacrylic acid) (PMAA) and poly amino acids like poly(L-arginine) (PAr), 
poly(L-lysine) (PLL) are widely used synthetic PELs.
5-11
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Figure 1.1. Schematic illustration of PEL structures: polycation (left), polyanion 
(middle) and polyampholyte (right). 
 
1.1.2. Origination, features and applications of PEL 
Natural occurring PELs are usually extracted or separated from plants. For 
instance, alginate (Alg), a widely used and carboxylic acid group containing PEL, is 
mainly originated seaweed. General extraction procedure described by Calumpong et 
al. includes incubation with acid, washing with water, dissolution of the minced 
seaweed with hot alkali solution, removal the insoluble residue from dissolved 
alginate, washing with acetone, dissolution in water, precipitation with ethanol and 
then drying.
12
 Sabra et al. reported that Alg also can be produced by bacteria such as 
several species of the genus Pseudomonas and Azotobacter.
13
 The methods for 
preparing synthetic PELs usually involves polymerization of ionic monomers or 
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chemical modification or functionalization of existing polymers.
14-16
 For instance, 
monodisperse PAA can be prepared by anionic polymerization of tertbutyl acrylate 
and following deprotection and purification.
17
 It also can be prepared by reversible 
addition-fragmentation transfer polymerization with trithiocarbonic acid dibenzyl 
ester and trithiocarbonic acid bis(1-phenylethyl) ester as chain transfer agents.
18
 An 
example about functionalization of existing polymers is the preparation of a synthetic 




Most PELs are water soluble as they can dissociate into charged polymer with 
its counter-ions in an aqueous solution, therefore, most PELs are electrical conductive 
in solution.
20-22
 Meanwhile, if there is no additional electrolytes in the solution, the 
PEL chain expands greatly due to electrostatic repulsion of charged groups on the 
chain while the expansion will disappear if the repulsion is screened by addition of 
extra electrolytes or PELs.
3
 The change of chain configuration in turn affects the 
viscosity and conductivity of PEL solutions which is known as the "PEL effect".
13-27
 
Such an effect plays a key role in a lot of interesting phenomena like the complex 
formation between oppositely charged PELs, self-assembly of PELs on a charged 
surface, salting out of proteins, protein-DNA interaction, molecular recognition and 
fluorescence quenching etc.
28-34
 These unique physical properties distinguish PELs 
from other polymers and subsequently their usage have being exploited in a wide 
range of industrial and biomedical fields. PELs have been used as dispersants, waste 
treatment agents, additives to modify solution viscosity and induce gelation, 
stabilizers for colloidal suspensions, flocculants, soap and detergent additives, water 
and soil conditioners, oil recovery agents, ion-exchange resins, membranes for lithium 
batteries and fuel cells etc.
35-41
 On the other hand, since the use of the PEL does not 
 Chapter 1: Introduction 
 5  
require any harsh organic solvent, the PEL is also very essential in biomedical 
applications.
16
 Moreover, as mentioned previously, most biological macromolecules 
per se are PELs. Thus, the importance of the PEL in biomedical applications is worth 
being elaborated on in a separate section. 
 
1.1.3. PEL for biomedical applications 
Both natural and synthetic PELs are widely used in the biomedical field 
because their similarity to biomacromolecules promises good biocompatibility and 
biodegradability.
42
 A few examples are given here to illustrate the importance of PELs 
in biomedical applications.  
1) In the field of dental and bone restorations, PELs can be used as adhesives 
and cements; for example, sodium alginate (Alg) and PAA are two commonly used 
materials which can form cement or hydrogel network after cross-linking with 






 The cement can be can formed at situated at the 
oral cavity site and also possesses long-term stability and cariostatic property. 2) In 
the area of tissue engineering, fibrous scaffold made from PEL complexation has been 
used for encapsulation of human mesenchymal stem cells which showed enhanced 
efficacy on its proliferation and chondrogenic and osteogenic differentiation.
45
 3) 
Some PELs are drugs such as sodium polystyrene sulfonate (PSS), a synthetic PEL 
which has been used to treat abnormally high potassium levels.
46
 Heparin, a natural 
occurring glycosaminoglycan, is a widely used injectable anticoagulant.
47
 4) In the 
area of blood contact applications, PEL materials are always used as surface coating 
to improve blood compatibility. For instance, physical adsorption or covalent binding 
of heparin onto hydrophobic material surfaces is the most commonly used approach to 
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improve blood compatibility.
16
 Other sulfonic PELs like poly(propyl sulfonate) 
surface have also been grafted onto a polyurethane surface which can interact with 
fibrinogen or promoted antithrombin and then significantly reduce platelet adsorption 
in a heparin-like way.
16
 The surface modification by PELs also affects cellular 
transport pathway, targeting drug delivery and cytotoxicity of nanoparticles (NP); this 
area is given further focus in this thesis. 5) In the area of intracellular gene delivery, 
PLL, Poly(ethylenimine) (PEI) and their derivatives are intensively studied PELs for 
gene delivery. They can improve cellular uptake ability and nucleus targeting ability 
of genes due to shape and charge change.
48,49
 6) The use of the PEL to prepare 
controlled release devices for biomedical applications is studied in-depth as most 
PELs are hydrophilic, non-cytotoxic, biocompatible, biodegradable and stimuli 
sensitive.
18
 Polyanions dissociate and expand at high pH values, whereas polycations 
protonate and expand at low pH values. Chain expansion results in volume and 
permeability change which affects drug release profiles. The PEL complex formed by 
the interaction between two oppositely charged PELs is the most prominent candidate 
for encapsulation of bioactive compounds as it is able to meet the profile of 
requirements of biocompatible polymer systems. The formation of PEL complex 
usually involves 3 stages (Figure 1.2): First stage is the formation of primary complex 
by electrostatic interactions. Second stage is the formation of intracomplex by new 
bonds or the correction of the distortions of the PEL chains. Third is the formation of 
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Figure 1.2. Schematic illustration of formation and aggregation of the PEL complex. 
Hydrogels and microcapsules are the two most widely used PEL complex 
encapsulation systems.
18
 Hydrogel is a hydrophilic three-dimension network which is 
cross-linked by chemical bonds or physical force and capable of holding a large 
amount of water.
51
 The cross-linking agent can be multi-valent ions or oppositely 
charged PELs. When a polyelectrolyte is combined with a multivalent ion of the 
opposite charge, it may form a hydrogel known as “ionotropic” hydrogel. When 
polyelectrolytes of opposite charges are mixed, they may form a hydrogel via a 
gelation process known as complex coacervates depending on their constitution, 
concentrations, as well as the ionic strength and pH of the solution. An ionotropic 
hydrogel formed by Alg and Ca
2+
 ions has been widely used for encapsulation of 
drugs, proteins and cells as its mild formulation condition is very suitable for 
biological systems.
52,53
 Microcapsules are generally fabricated via a so-called Layer-
by-Layer (LbL) technique with the use of oppositely charged PEL complexes like 
PSS/poly(allylamine) (PAH), or dextran sulfate (Dex)/PAr, and a removable template. 
LbL technique allows fine tuning on release profiles for various protein and drug 
delivery and this area is also the focus of this thesis.
28,42
 Hydrogel and microcapsule 
have a lot in common as they both have cross-linked networks. However, the 
spherical space is fulfilled by the hydrogel matrix with a lot of water molecules fixed 
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inside the matrix as well which means that the space for loading cargo is relatively 
limited. Conversely, the microcapsule only has a matrix at the shell part which could 
give more space for cargo loading. In despite of intense study, the potential of PELs 
for the encapsulation of bioactive compounds or even cells for applications in 
biomedicine, pharmaceuticals and biotechnology is far from being exhausted. 
 
1.2 Scope and Objective of Study 
The scope of this thesis is the design and application of different PEL 
materials for protein and drug delivery. Despite many advantages and successful 
examples of applying PEL materials in the biomedical field, significant challenges 
remained unresolved such as the kinetics and mechanism of macromolecule release 
from PEL microcapsules in the absence of external stimuli, which is not well 
understood. Hence, this research aims to better understand the factors that affect the 
release mechanism of PEL based carrier systems and explores the advantage of their 
application for controlled delivery of bioactive proteins and anticancer drugs in vitro. 
The specific objectives of this research are: 
 To identify the main factors influencing encapsulation of macromolecules into 
microcapsules and explain the mechanism of protein release from PEL 
multilayer microcapsules (chapter 3). 
 To tailor a microcapsule system suitable for basic fibroblast growth factor 
encapsulation and clarify the advantages of using the microcapsule as a carrier 
system for bioactive protein delivery (chapter 4). 
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 To prepare PEL grafted nanocomposites (NCs) and use the NCs to investigate 
the role of surface chemistry in anti-cancer drug delivery (chapter 5). 
Present studies will advance the knowledge of PEL microcapsule release 
control, enrich examples of protein delivery by PEL microcapsule and facilitate PEL 
based surface engineering for drug delivery. 
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2.1 Encapsulation technology for drug delivery  
The encapsulation technology is of a paramount importance in foods, 
cosmetics, personal care, pharmaceutical and biomedical industries. Taking 
pharmaceutical industry for example, the demand for suitable encapsulation systems 
to deliver a therapeutic agent in the needed amount, at the right time, with complete 
protection, to the specific location in the body and in a optimal dosage range to 
minimize side effects were responsible for $131.6 billion in globle market in 2010 and 
is expected to reach 175.6 billion by 2016.  
 
2.1.1 Particulate drug delivery systems 
A variety of particulate systems have been reported as effective controlled 
release carriers of therapeutic agents including inorganic particles, micro/nano-sphere, 
micelles, liposomes, hydrogel and micro/nano-capsules. 1) Inorganic particles. 
Inorganic particles with good biocompatibility such as carbon nanotube, silica, 
alumina, hydroxyapatite and titania have been used as carriers for drugs, proteins or 
enzymes. 
1-6
 Paul et al reported that insulin loaded hydroxyapatite nanoparticles could 
be used for oral administration with prolonged release efficacy.
7
 The carrier is able to 
protect cargo without swelling or porosity changes in solution. However, inorganic 
particles endure disadvantages like low loading capacity, poor biodegradability and 
slow elimination from the body. 2) Micro/nano-spheres. Micro/nano-spheres, also 
known as micro/nano-particles, are spherical bulk polymers particles with diameters 
in the micro or nanometer range. They can be prepared by phase separation or 
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precipitation, polymerization, emulsion-solvent evaporation, and spraying methods.
8
 
Emulsion-solvent evaporation method is the most commonly used at the lab scale. 
With this method, a solution containing the polymer is emulsified in a non-solvent 
phase containing stabilizers. The way of loading cargoes into polymer matrix relies on 
the property of cargoes. If they are solvophilic, cargoes can be co-dissolved with the 
polymer in a solvent. If they are solvophobic, cargoes may be suspended in the 
solvent as a finely ground dry powder. Due to their good biocompatible, high 
bioavailability, and sustained release ability, micro/nano-spheres have been widely 
used in several commercial products like Nutropin Depot which comprises 
recombinant human growth hormone encapsulated within poly(D,L-lactide-co-
glycolide) microspheres.
8
 Disadvantages of micro/nano-spheres include high cost of 
large-scale manufacturing, inactivation of drug during fabrication, and poor control of 
drug release rates. 3) Micelles. Micelles have a hydrophobic core capable of 
solubilizing lipophilic substances and a hydrophilic corona to stabilize the 
hydrophobic core in aqueous medium. One monodisperse polymeric material called 
dendrimers, which have hyper-branched structure and charged or polar terminal 
groups, can be considered as static, covalent micelles as well. The advantages of 
employing micelles to solubilize and deliver poorly water-soluble drugs include 
innate amphiphilic property and stability, small size effect (< 200 nm), and the narrow 
size distribution.
9
 Compared to low-molecular-weight surfactant micelles, polymeric 
micelles gained much attention because of their super lower critical association 
concentration, and better biocompatibility and biodegradibility.
10
 The most commonly 
used hydrophobic core polymers include biodegradable poly(lactic acid), poly(-
caprolactone), and poly(glycolic acid). On the other hand, poly(ethylene glycol) is 
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used as a hydrophilic part in most block copolymer micelles. Huh et al. encapsulated a 
anti-cancer drug paclitaxel with a micelle composed of PEG-b-poly(D,L-lactic acid) 
which increased its solubility up to 20% (wt/wt).
11
 The disadvantages of micelle 
carrier systems include low drug loading efﬁciency, poor blood stability after 
injection, and the difﬁculty in membrane transportation.12 4) Liposomes. Liposomes 
are formed by the self-assembly of dissolved natural phospholipid bilayers which can 
carry hydrophobic drugs in the lipid bilayer and water-soluble drugs in the 
hydrophilic inner core. The advantages imparted by liposomes are their abilities to 
load and protect various of therapeutic biomolecules, lack of immunogenic response, 
low cost, and mild formation conditions which minimize drug denaturation during 
encapsulation.
13
 The liposome is among one of the most important non-viral gene 
transfection carrier systems.
14
 There are definite drawbacks of using liposomes as a 
carrier system including quick elimination from blood, their tendency to rupture easily, 
lack of targeting and the risk of toxicity for positive charged liposomes.
15
 5) 
Hydrogels. Hydrogel, as mentioned in the introduction, are hydrophilic, physically or 
covalently cross-linked three-dimension network systems. As mentioned in the 
introduction part, hydrogels have been widely used for encapsulation of drugs, 
proteins and cells. Advantages of using hydrogels as a drug carrier system include 
high porosity, good biocompatibility and biodegradablility, and can be pH, 
temperature, ionic strength, electric field, and other environmental stimuli sensitive.
16-
19
 But they also frequently suffer from mechanical stability deficiency, durability 
issues, and permeability drawbacks.
17
 6) Micro/nano-capsules. Micro/nano-capsules 
have a micro or nano-size hollow cavity surrounded by a thin shell. The hollow cavity 
plays the role of a high capacity depot (unlike the matrix filled hydrogels) for cargo 
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loading while the shell serves as a tunable barrier to control the release rate and 
protect the drug from potential damages in the surrounding environment. This innate 
structural feature renders micro/nano-capsules high loading capacity and ideally 
suited for the encapsulation of bioactive agents such as proteins, peptides, and nucleic 
acids which will be elaborated later.
20
 Nevertheless, the classification is not strict. For 
example, the terms microcapsules and microspheres are often used synonymously. 
Some related terms such as “microbeads” and “beads” are used alternatively as well, 
especially for spherical particles with a large size and rigid morphology. 
 
2.1.2 Advantages of PEL based carrier systems 
Among the carriers mentioned above, PELs have been widely used for 
preparation of hydrogels and micro/nano-capsules, and modification of inorganic 
particles and micro/nano-spheres. PELs have certain advantages over uncharged 
polymers. First of all, carriers prepared with PELs have higher mechanical stability as 
the force held PELs together is usually electrostatic force which is stronger than 
hydrogen bond or Wan Der Waals force. Secondly, PELs are able to form multi-
layers of surface coatings outside the carrier to increase its suspension stability as the 
surface charge can overcome the thermal fluctuation caused instability. Thirdly, PELs 
can adsorb oppositely charged cargos which promises higher encapsulation efficiency 
(EE). Besides, PELs based carriers may specific immunological responses and other 
cellular interactions. For instance, Dex/Par based PEL microcapsules were able to 
target the local pulmonary antigen presenting cells and lymph nodes efficiently, 
making these PEL microcapsules a promising immune system for protection against 
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intracellular pathogens, such as mycobacterium tuberculosis and HIV. 
21,22
 Moreover, 
PELs usually originate from broad and renewable sources which guarantees low 
utility cost. For example, Alg can be obtained from seaweeds and bacteria. 
Since PEL materials have so many advantages, we also adopted PELs to 
constitute our carrier or as the functional layer. One polycation and four different 
polyanions have been used in our experiments (Table 2.1). Three of them, Dex, Hep 
and PSS have a strongly negatively charged sulfate group. Alg has a weakly charged 
carboxylate group. PAr is a strongly charged polycation which has both amino and 
imino groups. They have already been widely used in various biomedical applications 
mentioned in early parts of chapter 1 and chapter 2. Moreover, they are either 
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2.2 Preparation of PEL microcapsules and drug release from PEL 
microcapsules  
In the field of drug delivery, maintaining the drug in a therapeutic window or 
at optimal dosage which is enough to demonstrate drug efficacy while causing 
negligible or acceptable side effects is always desirable. As mentioned previously, 
microcapsules system is one of the most promising approach to address such 
controlled release issues.
23
 The preparation of microcapsule can be based on 
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evaporation, emulsion and suspension polymerization, interfacial cross-linking and so 
on.
24
 Among them, coacervation based LbL technique shows great advantages such as 





2.2.1 LbL technology for PEL microcapsule preparation 
This LbL technique was first introduced nearly 20 years ago for the purpose of 
planar surface modification and subsequently, its application in microcapsule 
preparation was found.
25-33
 Generally, the LbL process for preparing PEL 
microcapsules involves coating of charged PELs on a template, washing steps to 
remove excess, non-adsorbed PELs, reversal of surface charge by coating an 
oppositely charged PELs, repetition of the alternative coating until desired shell 
thickness or number of layers have reached and removal of the template (Figure 
2.1).
28
 Many PELs can be used as shell composition such as polyantions like synthetic 
PSS, PAA, carboxymethylcellulose (CMC); natural and biodegradable Alg, Dex, 
hyaluronic acid; polycations like synthetic PAH, PLL, PAr, natural and biodegradable 
chitosan (CT), and gelatin (GL) are the most commonly used candidates.
24-36
 The 
thickness of one layer usually ranges from a few nanometers to tens of nanometers 
and different combinations can be tailored for different purposes.
37
 On the other hand, 
the template usually ranges from hundreds of nanometers to tens of micrometers, thus 
popular template candidates include organic microparticle based polystyrene, 
melamine-formaldehyde, latex, poly(lactic acid), poly(lactic-co-glycolic acid), Alg 
hydrogel microbeads and inorganic microparticles based silica, calcium carbonate 
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(CaCO3), manganese carbonate, metal NPs which can be easily removed by treating 
with acids, organic solvents or coordinate agents.
29-46, 49, 50
 In some cases, the template 
can be preserved (usually biodegradable templates) for purposes such as pulsed drug 
delivery or direct coating on cargo crystal or the introduction of a magnetic 
property.
47,48 
If needed, it is still possible to change the permeability by coating further 
PEL layers after removal of the core.
32
 The cargo can be loaded into the 
microcapsules by adsorption onto the template before the shell formation which is 
known as the pre-loading routine or diffusion. Penetration through the shell by 
smartly adjusting its permeability with pH or ionic strength control after the hollow 
microcapsule formation is known as the post-loading routine. The preparation of 
microcapsules by the LbL process together with different loading routines is outlined 
in Figure 2.1. Specifically, Gleb et al. proposed a very effective loading method for 
the pre-loading routine which load the cargo during the formation of the core by a co-
precipitation process.
41
 As conditions for the co-precipitation process are very mild, 
this method is very suitable for the loading of bioactive proteins.
42,43 
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Figure 2.1. Schematic illustration of LbL technique for microcapsule preparation and 
different cargo loading routines: pre-loading routine (top) and post-loading routine 
(bottom). 
 
2.2.2 The mechanism of drug release 
One of the most frequently mentioned advantages of using microcapsules for 
controlled release is their fine permeability control.
24,54,55
 Better understanding of the 
governing factors is very important for microcapsule design and application. 
Generally speaking, one or more of the mechanisms affect the drug release kinetics 
from microcapsules: diffusion, osmosis, desorption and erosion. 
1) Diffusion. Diffusion is the most commonly involved mechanism wherein 
the loading drug penetrates the shell through the interstitial channels or pores on the 
shell. Diffusion of drug from microcapsules can be divided into two processes: 
interior and exterior diffusion.
56
 Interior diffusion describes that encapsulated drugs 
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transport from the inner cavity to surface of the carrier through the shell which is also 
the rate-limiting step in microcapsules. In general, if diffusion coefﬁcients is constant, 
diffusion in a microcapsule system can be described by Fick’s first law (equation 1):57 
         (1) 
where J: the "diffusion flux" (amount of substance per unit area per unit time),  
D: the diffusion coefficient, 
dC/dx: the concentration gradient across the shell. 
The diffusion process can be further classified into two classes based on initial 
drug concentration inside the carrier: below or above drug solubility in the carrier. In 
the case of initial drug concentration smaller than drug solubility, the drug 
concentration at inner surface of the membrane decreases with time. If the thickness 
and permeability of shell does not change, and the perfect sink condition maintains, 
the release will be independent of the carrier geometry, and the diffusion is first order 
kinetics controlled process (equation 2):
56
 
    (2) 
where Mt: the total amount of drug released at time t; 
Ct: the concentration of the drug in the medium at time t; 
M0: the initial amount of encapsulated drug; 
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V: the volume of the drug carrier; 
A: the total surface area of the device; 
l: the thickness of the membrane;  
D: the diffusion coefﬁcient of the drug within the shell; 
K: the partition coefﬁcient of the drug between the shell and the inner cavity. 
In the case of initial drug concentration exceeds the drug solubility in the 
carrier, the drug concentration at inner surface of the membrane is constant as the 
released drug will be replaced by dissolution of drug crystals or amorphous 
aggregates. If the thickness and permeability of shell does not change, and the perfect 
sink condition maintains, the release will be also independent of the carrier geometry, 
and the diffusion is zero order kinetics controlled process (equation 3): 
      (3) 
where Mt: the amount of drug release at time t;  
A: the total surface area of the carrier; 
Jlim the shell-limiting ﬂux;  
l: the thickness of the shell; 
D: the diffusion coefﬁcient of the drug within the shell; 
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K: the partition coefﬁcient of the drug between the shell and the inner cavity; 
Cs: the solubility of the drug in the inner cavity. 
Exterior diffusion describes that encapsulated drugs transport from surface of 
the carrier to the bulk medium which also obeys Fick’s first law. 
2) Osmosis: If the shell of microcapsule is semi-permeable to the loading 
cargo, an osmotic pressure difference between the inside and the outside of the 
microcapsule will be created and drives drug solution out of the microcapsule through 
small pores in the shell. A simple solution-diffusion model can be used to describe 
this process (equation 4):
58
 
       (4) 
where J: the "diffusion flux" (amount of substance per unit area per unit time),  
D: the diffusion coefficient, K: the sorption coefficient, (D·K is usually 
regarded as the permeability coefficient P) 
dC/dx: the concentration gradient across the shell. 
3) Desorption. Desorption is also a release controlling step in some cases due 
to strong chemical or physical interactions such as electrostatic attraction and 
hydrogen bond may form between the shell surface and drug molecules. When 
diffusion rate is less than desorption rate, desorption becomes a dominant rate 
controlling step. 
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4) Erosion. Erosion due to pH and/or enzymatic hydrolysis of the shell 
materials may cause drug release in an uncontrollable way which is also called burst 
release. There are also other factors which could trigger burst release from 
microcapsules such as the application of a magnetic field, laser or light irradiation or 
ultrasound and encapsulation of enzymes.
59-63
 In the case of anti-cancer drug delivery, 
burst release is ideally suited when the microcapsule makes contact with a targeted 
cancerous cell or tissue.
47,64
 
However, these simplified mathematical models of drug release from 
microcapsules face realistic difficulties due to great diversity in physical forms of 
microcapsules with regard to size, shape and shell composition. The presumption of 
these models such as constant permeability may not be realized in real situation. 
Sometimes the release process consists of two or more mechanisms rather than one 
single mechanism. Moreover, these models concern only drug transport in the model 
system, not in the living organism. To describe the mechanism of drug release in vivo 
various additional phenomena such as protein binding, active and passive drug uptake 
into cells, interactions with extra- and intracellular compounds need to be taken into 
account. Current mechanistic realistic and mathematical theories cannot take all these 
phenomena appropriately into account. Even if we cannot get a perfect mathematical 
model, from the process engineering point of view, a few impact factors can be 
pointed out based on various studies concerning the release characteristics. For 
instance, the impact of the concentration gradient across the PEL shell, and 
permeability of the shell can be found in nearly all controlled release situations.
34,35 
Thus, one or more of the following factors might be used to control the release rate. 
Factors affecting the concentration gradient may include: the cargo loading routine 
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and encapsulation efficiency (EE) which can affect the cargo concentration inside the 
microcapsule, the volume of the release medium and the frequency of medium 
refreshment. Once the concentration gradient is fixed, the permeability of the shell 
becomes the key and direct issue that controls the release rate. We assume 
permeability is constant in order to give above mathematical models. However there 
are many factors that can affect the permeability such as pH, temperature and ionic 
strength of the medium, and composition and thickness of the shell.
32,33,38,67-69
 On the 
other hand, since the shell of microcapsules is composed by PELs, the pH and ionic 
strength could affect the charge distribution and confirmation of the PEL chains and 
then change the permeability of the whole shell.
70
 Also, shell sensitivity to pH and 
ionic strength is also related to the PEL composition and thickness.
38,68,71-73
 
Microcapsules composed by PELs with weakly charged groups and thin layers are 
inclined to be more sensitive to pH and ionic strength.
71
 In some cases, the extreme 
pH condition leads to the eruption or dissociation of the microcapsule. 
 
2.2.3 Applications of microcapsules as carriers for encapsulation of bioactive 
cargos 
Although microcapsules have been widely used in applications like 
pharmaceuticals, cosmetics, the agricultural industry, food technologies, the textiles 
industry and printing industry for many years, application of PEL microcapsules 
prepared by LbL technique for delivery of bioactive compounds such as cells, 
proteins, vaccines, enzymes, drugs and genes have attracted strong research interests 
in recent years.
47,51,52,65
 This is mainly because these types of PEL microcapsules 
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show unrivalled advantages related to the mild and purely aqueous preparation 
conditions, and the versatility of useful polymers for LbL assembly. 
A few examples of these are given here. For cell encapsulation, microcapsules 
composed with PSS/PAH and PSS/poly(diallyldimethyl-ammonium chloride) have 
been used for human pancreatic islets encapsulation.
74
 The microcapsule showed 
good maintenance on the bioactivity of islets without affecting the insulin production 
and release. Meanwhile, it also provided protection against islet-specific antibody 
recognition. For protein delivery, post-loading of transforming growth factor-1 
(TGF-1) into heparin/PAr microcapsules with pre-loaded heparin was reported.75 
These microcapsules could successfully maintain the bioactivity of TGF-1 and 
stimulate myofibroblast differentiation and contraction in vitro. For vaccine delivery, 
microcapsules with the biodegradable combination of Dex/PAr were used for co-
delivery of the human immunodeficiency virus (HIV-1) p24 antigen and poly I:C 
which showed enhanced HIV-1-specific immune responses both in vitro and in vivo.
76
 
For enzyme delivery, microcapsules prepared with a biodegradable dex/protamine 
combination were used for encapsulation of peroxidase.
63
 The peroxidase showed up 
to 57% of the native enzyme activity which remained stable for 12 months after 
encapsulation and its release rate was affected by pH and shell thickness. For drug 
delivery, the antibiotic drug amoxicillin has been loaded into Alg/CT based 
microcapsules where the role of the microcapsule was protection of the drug from 
degradation in an acidic environment and enhancement of the drug loading efficacy 
and mucoadhesive efficiency in this case.
77
 For gene delivery, DNA can be loaded 
into microcapsules either by template adsorption or directly used as the microcapsule 
shell composition.
78,79
 The DNA adsorbed onto MnCO3 core and then coated with a 
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combination of chondroitin sulfate and PAr maintained its natural double-helix 
structure after the core removal.
80
 In another case of DNA/PLL composed 
microcapsules, the release rate of DNA and incorporated model drug could be both 
adjusted by ionic strength control.
81
 In summary, PELs have been widely used for 
biomedical applications and will continue to play a very important role in this field. 
2.3 PEL modified NC and impact of surface engineering  
The micro-size PEL capsule system mentioned above is mainly designed for 
extracellular delivery and maintaining the drug concentration at an optimal range at 
tissue level. However, for most intracellular applications, carriers with a size over 1 
micrometer cannot be internalized by cells effectively.
82-85
 Meanwhile, a fine 
controlled release inside cell cytoplasm is not always desired. Hence, the design of 
nano-sized carriers is very important for intracellular studies. Cheap and 
biocompatible inorganic NPs like silica, gold, carbon black, carbon nanotubes, 
titanium dioxide (TiO2), zinc oxide, iron oxide etc. have been widely used for 
different delivery purpose.
86-91
 For example, the TiO2 NPs showed anticancer efficacy 
enhancement and side effect attenuation when it was used for delivery of the anti-
cancer drug doxorubicin.
93
 However, the NP alone as a drug carrier has some 
drawbacks such as low loading capacity, poor stability in solution and inert surface 
property.
92
 As mentioned in the introduction, PEL is very suitable for surface 
modification. So the PEL modified NC is possibly a good alternative for such 
applications.
94
 Therefore, the preparation of NC and its advantage for biomedical 
applications will be discussed in the following section. 
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2.3.1 Preparation of PEL modified NCs 
The preparation of polymer modified NC can be divided into two strategies: 
physical adsorption of polymer onto NP surface or covalent chemical bonding 
(grafting) of polymer onto NP. Physical adsorption is mainly driven by van der waals' 
force and electrostatic attraction.
95
 For the polymers grafting strategy, there are 
generally three routines to realize in general: surface modification, extra initiator 
addition and in situ polymerization.
96-98
 In the surface modification routine, for 
instance, azo, peroxide , and peroxyester groups have been introduced onto NPs such 
as silica surface to initiate the radical graft polymerization of vinyl monomers and 
give the corresponding polymer-grafted silica.
99-101
 To add extra initiators, the 
initiator can be added to emulsion of both monomers and NPs and then 
polymerization can be triggered by a stimulus such as temperature change. NPs will 
be embedded into polymer matrix after polymerization. For in situ polymerization, 
NPs per se can be used as a polymer initiator under an external stimulus such as photo 
irradiation. This is the simplest routine to carry out surface modification, however, 
only a few NPs like TiO2 and carbon doped TiO2 were found to have such ability.
98,102
 
TiO2 is very biocompatible, low in cytotoxicity and consequently has been widely 
used in biomedical applications.
103
 Hence, we will take TiO2 as an example to 
illustrate the principle of in situ polymerization. Hoffman et al. reported that colloidal 
suspensions of TiO2 particles under UV irradiation are able to in situ photo-initiate 
polymerization of a wide variety of vinyl monomers, and proposed a mechanism of 
free radical chain propagation.
102
 Since PEL is also a kind of polymer, PEL modified 
NCs can be prepared by similar strategies. 
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Figure 2.2. Schematic illustration of free radical chain propagation based in situ 
photo-polymerization from TiO2 surface.  
 
2.3.2 Impact of NCs surface chemistry on its biomedical application 
Covering the surface of NPs with polymer to form NCs usually offers benefits 
such as enhanced stability, improved processibility and more interactive functionality 
to NPs.
92,94
 In biomedical application in particular, the engineer of surface chemistry 
could turn the bio-inert surface of NPs into a bio-interactive surface which will 
expand the use of NPs or NCs in this area. Generally speaking, the engineering of 
NPs surface chemistry in biomedical application can enhance stability in the 
physiological environment, improve the biocompatibility, increase internalization 
efficiency of the NPs, amplify drug sensitivity, and create a synergistic and cell 
targeting effect.
92,104-107
 A few examples of surface engineering for biomedical 
applications are given here. Modification of surface with sulfonic groups always leads 
to improved blood compatibility. Surface modification of NP with positively charged 
PELs like CT, PEI and PLL are always used for non-viral gene delivery 
application.
105,108-112
 Paul et al. reported that the surface modification of TiO2 NPs 
with -NH2 and -OH groups showed a significantly higher cancer cell killing effect 
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than that of -COOH as NP-mediated cell membrane disruption leads to cell death.
106
 
In another study, maghemite NP surface modified with PAA shows higher affinity for 
cellular membrane than dextran and BSA coated ones, this is mainly due to 
electrostatic interactions and its endocytic pathways through cells is most probably 
the clathrin-dependent endocytosis.
113
 In summary, the role of PELs in surface 
modification of NPs is very important and requires continuous research input. 
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3.1 Introduction  
Microcapsules fabricated via Layer-by-Layer (LbL) adsorption of oppositely 
charged PELs are proved to be a versatile reservoir system for bio-active 
macromolecules.
1
 For instance, loading of multilayer capsules with enzymes, 
polymers, dyes, proteins, and drugs has been demonstrated.
2-6
 Among the strategies 
for encapsulation of macromolecules in PEL multilayer microcapsules, two 
approaches are highlighted as the most commonly used for biological compounds: (i) 
loading of prefabricated PEL multilayer microcapsules with the desired species; (ii) 
encapsulation assisted by porous inorganic template (e.g., CaCO3 or mesoporous 
silica micro-particles), which coprecipitates the macromolecules from the surrounding 
medium, followed by subsequent coating of the loaded microparticles with 
multilayers of oppositely charged PELs. 
7-10
 The effectiveness of these polymeric 
multilayer microcapsules in practical applications strongly depends on their ability to 
release incorporated materials in regulated fashion. A number of recent publications is 
devoted to the investigation of main factors influencing the release profile of low-
molecular-weight drugs from polysaccharide microcapsules. Ye et al. and Zheng et al. 
revealed the effect of medium pH, microcapsule shell thickness, annealing treatment, 
postcoating, and cross-linking on insulin release.
6,11
 Han and coworkers demonstrated 
that the release of anticancer drug daunorubicin from CT and alginate glutaraldehyde 
cross-linked microcapsules was determined by the concentration gradient across the 
capsule shell due to a highly permeable polysaccharide network.
12
 Multilayer capsules 
of different shell thickness and composition were proved to be effective to provide 
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prolonged release of water insoluble drugs, for example, furosemide, ibuprofen, and 
dexamethasone.
13-15
 Low-molecular-weight protamine dissolved in the aqueous 
medium was found to undergo reversible exchange with protamine molecules bound 
to Dex or bovine serum albumin (BSA) in the form of multilayer complex on 
colloidal microparticles.
16
 Stimuli-triggered release from PEL microcapsules was 
reviewed elsewhere.
17
 However, the factors affecting kinetics and mechanism of 
macromolecule release from PEL microcapsules in the absence of external stimuli are 
not well understood. Moreover, as mentioned in chapter 2, the constant permeability 
presumption used by most mathematical models is not always true which need to be 
checked in every real case if we want to apply those models. Detailed studies will 
allow customization of microcapsule properties that provides a desired rate of release 
for encapsulated macromolecules corresponding to their optimal biological and 
therapeutic effect, which will facilitate the application of PEL microcapsules in drug 
formulation and drug delivery. 
The release of encapsulated materials from microcapsules is driven by the 
concentration difference between the capsule interior and the external medium where 
the multilayer polymeric shell acts as an obstructive membrane barrier for liberating 
compounds. Therefore, permeability of the shell plays a key role in the process. In the 
case of microcapsules fabricated via LbL adsorption of oppositely charged PELs, 
shell permeability can be controlled by varying its composition and thickness (related 
to the total number of deposited layers). In the current work, the release mechanisms 
of model protein drug, TRITC-BSA, encapsulated using two different approaches 
(“preloading” and “postloading”), are comparatively studied in dependence of 
the chemical composition of polyanion (Dex or Alg) applied for multilayer shell 
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assembly and the number of adsorbed double layers. Polymer couples (Dex/PAr and 
Alg/PAr) were chosen as shell constituents because of their biocompatibility and 
shown ability to degrade upon cellular uptake.
18
 The release profiles obtained at 
different volume of surrounding medium and frequency of medium refreshment were 
used to elucidate about the mechanism of protein release from respective 
microcapsules. The aim of our study is to reveal the main factors influencing capsules' 
loading with macromolecules and the mechanism of their release. TRITC-BSA was 
selected as the model protein drug because of its availability and relatively low cost. 
Although a new set of experiments has to be performed with other desired therapeutic 
compounds, this article, nevertheless, focuses on clarifying the potential of multilayer 
PEL capsules as a control release system. 
3.2 Experimental Section   
3.2.1 Materials 
Tetramethylrhodamine isothiocyanate labeled bovine serum albumin (TRITC-
BSA), Dex, (MW. 9 000~20000), Alg, (MW. 8194), PAr, (MW. > 70000), calcium 
chloride dihydrate (CaCl2), anhydrous sodium carbonate (Na2CO3), sodium chloride 
(NaCl), ethylenediaminetetra-acetic acid trisodium salt (EDTA) were purchased from 
Sigma-Aldrich. All chemicals were used as received without further purification. 
Deionized water (DI) with specific resistivity higher than 18.2 MΩ·cm-1 from a three-
stage Milli-Q Plus 185 purification system was used in the experiments. 
 
3.2.2 ‘Pre-loading’ of protein into PEL microcapsules 
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Pre-loading of TRITC-BSA into PEL microcapsules was performed according 
to LbL process.
7-10
 LbL process for preparing PEL microcapsules usually involves 
coating of charged PELs on a template, washing steps to remove excess, non-
adsorbed PELs, reversal of surface charge by coating an oppositely charged PELs, 
repetition of the alternative coating, and removal of the template. By varying the 
composition and thickness (number of layers), the release rate of the microcapsule can 
be tuned easily. In this experiment, 2.0 ml of TRITC-BSA water solution (5 mg/ml) 
was mixed with 1.0 ml of 1.0 M CaCl2 and 1.0 ml of 1.0 M Na2CO3 aqueous solutions 
under vigorous agitation for 15 seconds. The synthesized CaCO3 microparticles 
containing TRITC-BSA were washed twice with DI water via subsequent 
centrifugation/resuspension steps to remove residual salts and non-adsorbed protein 
from the medium. Multilayer shells were then assembled by immersing successively 
the CaCO3/TRITC-BSA microparticles into aqueous solutions of polyanion (Dex or 
Alg) and polycation (PAr) for 15 minutes until the desired number of layers was 
achieved. PELs used for capsule fabrication were dissolved in water in concentration 
of 2.0 mg/ml in presence of 0.5 M NaCl. After each deposition step, the protein 
loaded microparticles were centrifuged. The supernatant was replaced with the pure 
water and the particles were resuspended. Washing procedure was applied twice to 
ensure no uncoupled PEL remained in the sample. CaCO3 template was then removed 
by EDTA treatment. For this purpose, multilayer coated CaCO3/TRITC-BSA 
microparticles were dissolved in 0.2 M EDTA solution at pH 7.0 for 30 min followed 
by two times of washing with water. (To ensure complete CaCO3 decomposition, the 
described EDTA treatment procedure could be repeated if necessary.) Supernatant 
obtained upon core dissolution and sample washings were collected for further 
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analysis of the TRITC-BSA concentration. 
 
3.2.3 ‘Post-loading’ of protein into PEL microcapsules 
Hollow microcapsules were synthesized in similar fashion according to the 
LbL coating and following EDTA treatment procedures mentioned above, except that 
TRITC-BSA was only loaded after formation of hollow microcapsules. After 1 day of 
incubation in 2.0 ml of 5.0 mg/ml TRITC-BSA water solution at 37 
o
C, loaded 
microcapsules were washed twice with water. Concentration of TRITC-BSA was 
measured in each supernatant to determine the amount of encapsulated protein and EE. 
 
3.2.4 Determination of EE and amount of released protein 
Fluoromax 3 (Jobin Yvon Inc.) with xenon arc-lamp, 150 w and 555 nm 
wavelength was used to measure TRITC-BSA concentration in an aqueous solution. 
Fluorescence intensity of rhodamine was detected at 572 nm (±1 nm). A calibration 
curve was obtained using the measured values of fluorescence intensity of TRITC-
BSA solutions of known concentration. Unknown samples were diluted with 1x 
phosphate buffer saline (PBS) at pH 7.4 to ensure that measurements lie within the 
linear range of the calibration curve. 
In case of the ‘pre-loading’ approach, the amount of protein loaded in the 
whole bunch of CaCO3 microparticles was determined as a difference between the 
total amount of protein used for CaCO3 co-precipitation (10.0 mg) and the amount 
lost over shell assembly. For that purpose, TRITC-BSA concentration was measured 
in all supernatant collected during each step of microcapsule fabrication. In the ‘post-
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loading’ routine, the amount of unloaded protein and overall loss during capsules’ 
washing were deducted from the initial amount (10.0 mg) of TRITC-BSA added into 
the system to give the total amount of encapsulated TRITC-BSA. To investigate 
protein release, TRITC-BSA-loaded microcapsules were resuspended in desired 
volume of liquid (pure water or 0.15 M NaCl solution) and allowed to incubate at 37 
o
C in carefully sealed centrifuge tubes. After the prescribed time of incubation, the 
samples were centrifuged, then the concentration of TRITC-BSA in the supernatant 
was measured. The supernatant used in fluorescence measurements was then placed 
back into the same centrifuge tube from which it had been collected, and the capsules’ 
pellet was resuspended again. If the procedure required medium exchange, the full 
volume of supernatant obtained after capsules’ centrifugation was replaced with the 
same amount of fresh (protein-free) aqueous medium. The cumulative amount of 
released TRITC-BSA was then integrated from each measurement. 
 
3.2.5 Scanning electron microscopy (SEM) 
SEM measurements were conducted on a Gemini Leo instrument operating at 
an acceleration voltage of 2 kV. For sample preparation, a small droplet of 
microcapsules’ suspension was placed on a conductive carbon film and left to dry 
overnight. The sample’s surface was then coated with gold before taking SEM images. 
 
3.2.6 Confocal laser scanning microscopy (CLSM) 
Optical images of TRITC-BSA containing microcapsules were obtained on a 
Leica TCS SP2 AOBS CLSM system equipped with a 63×/1.4 oil lens (HCX PL Apo, 
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Leica Microsystems, Germany) objective. The excitation (λex) and emission (λem) 
wavelengths (λex=543 nm, λem=596 nm) were used for capsules’ visualization. 
 
3.3 Results and Discussion 
3.3.1 Amount of encapsulated TRITC-BSA 
In order to understand the mechanism of protein release from PEL capsules, 
the most crucial parameter to be taken into account is the total amount of protein 
contained or accumulated within the capsules. It has been observed that protein 
released into surrounding media from one capsule might be re-adsorbed into other 
capsules.
4
 Hence, we only consider the total amount of encapsulated protein in the 
entire capsule suspension. We observed that the total volume occupied by capsules 
remained constant (approximately 70 l) in all experiments. Some loss of capsules 
during continuous washing steps could happen but did not exceed a few percent. 
In our study on the mechanism of protein release, we compared two 
approaches of encapsulation: i) protein co-precipitation in CaCO3 particles followed 
by multilayer assembly, so-called ‘pre-loading’ and ii) ‘post-loading’ where protein 
was accumulated in pre-formed capsules assembled on pure CaCO3 particles. The 
results from both approaches were compared on the basis of identical PEL pairs and 
number of polymer layers. 
Our ‘pre-loading’ procedure demonstrated an EE of 80 % at the stage of 
protein/CaCO3 synthesis (i.e. 8 mg of protein co-precipitate in CaCO3 microparticles 
and 2 mg of protein remained free in continuous phase) (Table 3.1). In this approach, 
the amount of protein incorporated inside CaCO3 particles is determined by 
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protein/CaCO3 interaction during co-precipitation, and should not depend on materials 
applied for multilayer shell fabrication. Decomposition of calcium carbonate template 
entailed rapid release of substantial amount of protein molecules, which were 
apparently weakly retained by PEL shell. The amount of protein released at core 
dissolution (so-called ‘burst release’) was about 30 % and 24 % of co-precipitated 
protein in case of (Dex/PAr)3 and (Alg/PAr)3, respectively. The amount of TRITC-
BSA remained inside the corresponding microcapsules would be 5.5 mg and 6.0 mg. 
Thicker PEL shells comprising 5 double layers of PELs allowed better retaining in 
comparison with those composed of 3 double layers. (Dex/PAr)5 and (Alg/PAr)5 
microcapsules retained 6.5 mg and 7.0 mg of TRITC-BSA, respectively. Our 
observations showed that protein ‘burst release’ from Alg/PAr capsules was lower 
than that from Dex/PAr capsules of the same thickness. The ability of Alg/PAr’s to 
retain protein better is possibly due to effective adsorption of protein by Alg in the 
multilayered shell. It has been known that the carbohydrate-based polymer does offer 
a stable environment for proteins.
19,20
 Besides, retention of BSA by PEL 
microcapsules fabricated from Alg in the capsule cavity has also been demonstrated.
21
 
Furthermore, Alg/PAr PEL shell fabricated in a LbL fashion can be denser than that 
of Dex/PAr at a given number of adsorbed double layers. Indeed, Alg has only weakly 
acidic carboxyl groups, whereas Dex is a strong PEL due sulfonic acid functionality. 
Fewer amounts of charged segment per chain might lead to denser packing of Alg 
within the layer due to lower electrostatic repulsion of same charged PEL segments in 
the network. 
 
Table 3.1. Amount (mg) of TRITC-BSA encapsulated in the bunch of microcapsules 
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(Dex/PAr)3 (Alg/PAr)3 (Dex/PAr)5 (Alg/PAr)5 












2.5 36 6.0 87 2.6 38 6.3 91 
a
 Initial amount of protein loaded was 10 mg in each loading routine. Each data is a mean value of 3 
independent experiments on TRITC-BSA encapsulation. The standard deviation is 5 % 
 
As it can be clearly seen from Table 3.1, the amount of ‘post-loaded’ protein 
also showed strong dependence on the multilayer shell composition. For instance, the 
effectiveness of (Alg/PAr)3 microcapsules to encapsulate TRITC-BSA was more than 
2.5 times higher in comparison to microcapsules composed of (Dex/PAr)3. 
EE for ‘pre-’ and ‘post-loading’ approaches are almost equal for 
microcapsules composed of Alg/PAr. However, ‘post-loaded’ Dex/PAr microcapsules 
contained considerably less TRITC-BSA than ‘pre-loaded’. Though, the Dex/PAr 
multilayer composition is capable to retain TRITC-BSA over inorganic template 
dissolution, it does not facilitate protein accumulation in ‘post-loading’ routine. The 
possible explanation of the results observed is that Alg essentially provided a gel 
matrix for adsorption of protein within the shell.
19-21 
 
3.3.2 Influence of the capsule’s shell design on release of TRITC-BSA 
To investigate the influence of shell composition and thickness on protein 
release, microcapsules composed of (Dex/PAr)3, (Alg/PAr)3, (Dex/PAr)5 and 
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(Alg/PAr)5 ‘pre-loaded’ with TRITC-BSA were placed in 1 ml of aqueous medium 
containing 0.15 M of NaCl and allowed to incubate at 37 C. The amount of released 
protein was determined after 24, 48 and 72 hours of incubation. The surrounding 
medium was fully refreshed at each time point, modeling external consumption of 
released protein (as it happens, for instance, upon release of therapeutic compounds in 
the presence of receiving cells). Figure 1 displays the obtained protein release profiles 
(a) and the calculated release rates (b) for Dex/PAr and Alg/PAr microcapsules of 
different thickness. In this work, the cumulative release plotted versus time was 
evaluated as M(t)/M. M(t) is the total mass of protein, which would be released at 
time t, and M is the total mass of protein, which would be released at infinite time 
into an infinite volume (i.e. all the protein present in the capsules after CaCO3 
dissolution (refer Table 3.1 for specific values)). It can be seen, that release of 
encapsulated TRITC-BSA was a slow process influenced by both capsule shell 
thickness and composition. Capsules comprising 3 polymer double layers released the 
protein faster and in higher amount than those with 5 double layers in their shell.  On 
the other hand, Dex/PAr pair facilitated a better release in comparison with Alg/PAr 
at thinkness of 3 double layers. E.g. the amount of TRITC-BSA released from 
(Dex/PAr)3 capsules was 30 % higher than from (Alg/PAr)3 ones. Thicker shells of 
each composition were almost equally retentive. The release from (Dex/PAr)5 and 
(Alg/PAr)5 capsules was 0.23 mg and 0.24 mg of TRITC-BSA respectively. 
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Figure 3.1. Cumulative release (a) and release rate (b) of TRITC-BSA from Dex/PAr 
and Alg/PAr microcapsules into aqueous medium (V = 1 ml, T = 37 C). Shell design 
/ content of aqueous medium: (Dex/PAr)3 / 0.15 M NaCl (—●—), (Alg/PAr)3 / 0.15 
M NaCl (—□—), (Dex/PAr)5 / 0.15 M NaCl (—○—), (Alg/PAr)5 / 0.15 M NaCl (—
■—), (Dex/PAr)3 / pure water (----), (Alg/PAr)3 / pure water (--▼--).Digits in panel 
(a) display the amount of TRITC-BSA released from microcapsules into 0.15 M NaCl 
medium over 72 hours of incubation. Aqueous medium in the samples was fully 
refreshed every 24 hours. 
 
The characteristic feature of protein release from PEL microcapsules is the 
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significantly higher release rate over the first 24 hours of capsules incubation than 
over the following 48 hours (Figure 3.1b). Starting from the 25
th
 hour of incubation, 
the TRITC-BSA release rate slowly decreased with time in case of (Dex/PAr)3 and 
(Alg/PAr)3 microcapsules. Based on the mechanisms mentioned in chapter 2, this 
kind of release style usually indicates the release is mainly controlled by diffusion 
with protein concentration below its solubility inside the cavity. And desorption may 
also have some effect here. The rate of protein release from the thicker capsules of 
each investigated composition ((Dex/PAr)5 and (Alg/PAr)5) does not depend on time 
and follows zero-order kinetics over the same duration. This is possible because, the 
permeability decreases as the shell becomes thicker, and then the internal diffusion 
rate becomes less than desorption rate which turns the release mechanism from 
diffusion control to desorption control. A detail explanation and hypothesis will be 
given in a later part. 
The addition of salt to surrounding medium might influence capsule 
permeability to macromolecules due to breakage of bonds between oppositely charged 
PELs. Indeed, the addition of 0.5 M NaCl remarkably increased permeability of 
microcapsules composed of sodium poly(styrene sulfonate)/poly(allylamine 
hydrochloride).
22
 In our experiments, the effect of the presence of 0.15 M NaCl on 
release of TRITC-BSA from (Dex/PAr)3 and (Alg/PAr)3 microcapsules was 
determined to be within the limit of statistical error (Figure 3.1a). 
The role played by capsules’ shell as a tool to tune the release of encapsulated 
protein is revealed in Figure 3.2, where the total amount of released TRITC-BSA is 
plotted versus its concentration in one capsule. (Protein concentration in one capsule 
was estimated considering the total volume occupied by the pellet of capsules’ bunch 
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of 70 l and the average capsule radius of 1 m. The data for all investigated 
formulations are shown in Table 3.1.) It can be seen, that (Dex/PAr)3 microcapsules 
were able to release more protein than the other studied formulations, despite of the 
initial lowest concentration difference between the capsule’s interior and the 
surrounding medium. In contrast, (Alg/PAr)5 shells, which initially contained the 
highest amount of TRITC-BSA exhibited the lowest release. Thus the amount and the 
rate of protein release are determined by the kinetics of protein diffusion through the 
multilayer shell and can be tuned by varying the shell design. 
 
Figure 3.2. TRITC-BSA release data for microcapsules of different design versus 
initial concentration of protein in one capsule. 
 
3.3.3 Influence of concentration gradient on release of TRITC-BSA 
Figure 3.3 displays the profiles (a) and the rate (b) of protein release from 
(Dex/PAr)3 and (Alg/PAr)3 capsules over 72 hours of incubation in 0.15 M NaCl 
solution in dependence on the volume of surrounding medium. The concentration of 
released TRITC-BSA in bulk phase was examined every 24 hours without medium 
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refreshment at each time point. Similar to that in Figure 3.1, the protein release rates 
were significantly (3 - 5 times) higher during the first 24 hours of capsules’ incubation 
and almost independent of time for the following 48 hours. The capsules in each 
investigated composition showed a tendency to release more protein  as volume of 
medium increased. (Alg/PAr)3 shells were more retentive than those (Dex/PAr)3 in all 
cases. Larger volume of the bulk medium corresponded to higher rate of TRITC-BSA 
release from microcapsules, although, the total amount of released protein remained 
relatively low. For instance, the cumulative release of protein into 10 ml of salt 
solution from (Dex/PAr)3 and (Alg/PAr)3 microcapsules was 16 % and 13.5 %, 
respectively. 
 
Figure 3.3. Cumulative release (a) and release rate (b) of TRITC-BSA from 
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Dex/PAr and Alg/PAr microcapsules into 0.15 M NaCl solution (T = 37 C) in 
dependence on the volume of the medium. Shell design / volume of aqueous medium: 
(Alg/PAr)3 / l ml (-□-), (Alg/PAr)3 / 3 ml (-○-), (Alg/PAr)3 / 10 ml (--), (Dex/PAr)3 / 
1 ml (-■-), (Dex/PAr)3 / 3 ml (-●-), (Dex/PAr)3 / 10 ml (-▼-). 
 
Regular medium refreshment that helped to sustain concentration gradient 
across capsules’ shell was found to facilitate higher protein release. The cumulative 
release of TRITC-BSA from (Dex/PAr)3 and (Alg/PAr)3 microcapsules into 1 ml of 
0.15 M NaCl was up by 3 % and 2 %, respectively, if the medium was refreshed every 
24 hours (Figure 3.1 and Figure 3.3). Hourly medium refreshment sped up protein 
release even more significantly (Figure 3.4). Visual inspection revealed that the 
release from both (Dex/PAr)3 and (Alg/PAr)3 microcapsules at hourly medium 
refreshment has zero-order kinetics during the 3 hours of observations. Release rates 
obtained from linear regression analysis of the corresponding regions in the release 
curves (Figure 3.1 and Figure 3.4) are shown in Table 3.2. According to the data, the 
release rates for (Dex/PAr)3 and (Alg/PAr)3 microcapsules are in direct relationship 
with frequency of medium refreshment. 
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Figure 3.4. TRITC-BSA release from ‘pre-loaded’ PEL multilayer microcapsules 
composed of (Dex/PAr)3 (-∆- and -▲- (a)) and (Alg/PAr)3 (-○- and -●- (b)) into 
aqueous medium (V = 1 ml, 0.15 M NaCl, T = 37 C). Open symbols show data 
recorded after 1, 2, 3 and 75 hours of incubation, closed symbols display the protein 
release measured after 72, 73, 74 and 75 hours of incubation. Aqueous medium in the 
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Table 3.2. TRITC-BSA release rate from (Dex/PAr)3 and (Alg/PAr)3 microcapsules 







Release rate, g/hour 
Total release over 75 
hours, mg 
Frequency of medium 
refreshment 
1 hour 24 hours 72 hours 
(Dex/PAr)3 
‘Pre-loaded' 62 11 6 0.63 
‘Post-loaded' 124 - 20 2.09 
(Alg/PAr)3 
‘Pre-loaded' 92 9 4 0.52 
‘Post-loaded' 186 - 11 1.66 
a
Aqueous phase conditions: 0.15 M NaCl, V = 1 ml, T = 37 C. 
 
Protein release upon hourly medium refreshment performed over the first 
course of incubation was nearly 4 % of the total amount of TRITC-BSA contained 
after CaCO3 core dissolution. In general, the decrease in TRITC-BSA concentration 
inside the microcapsules should slow down its subsequent release into a fresh medium 
of the same volume due to lower concentration difference between the capsules’ 
interior and medium. In order to verify this, protein loaded (Dex/PAr)3 and (Alg/PAr)3 
microcapsules were first allowed to incubate over 72 hours in 1 ml of 0.15 M NaCl 
solution followed by extraction of the aqueous phase. Then the samples were refilled 
with the same volume of fresh NaCl solution. The concentration of released TRITC-
BSA was further analyzed hourly over subsequent 3 hours of incubation comprising 
full medium refreshment at each time point. For each of the investigated PEL shell 
composition, the release curves recorded through different pathways were 
characterized by similar slope, firstly, in the regions corresponding to protein release 
over 72 hours without medium refreshment and, secondly, in the regions of hourly 
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medium refreshment. Thus the observed decrease of protein concentration inside the 
capsules did not slow down the release rates. 
Our results revealed that the influence of concentration gradient on release of 
TRITC-BSA from (Dex/PAr)3 and (Alg/PAr)3 microcapsules is of two kinds. On one 
hand, the increase in volume of surrounding medium increased protein release rates. 
On the other hand, we did not observe apparent decrease in the release rate when the 
concentration of protein within one capsule was decreased. In such a way, higher 
volume of medium or regular medium refreshment have most likely shifted the 
adsorption/desorption equilibrium at the outer surface of the capsules’ shell, 
facilitating desorption of protein molecules. Faster desorption of TRITC-BSA from 
the capsule surface, in turn, sped up diffusion of other protein molecules located 
deeper in the shell. The TRITC-BSA release rate was thus determined by the kinetics 
of protein desorption from the PEL network and molecules’ diffusion through the 
shell, instead by protein concentration inside the capsule. 
 
3.3.4 Influence of loading routine on release of TRITC-BSA 
The release curves and associated release rates for (Dex/PAr)3 and (Alg/PAr)3 
microcapsules ‘post-loaded’ with TRITC-BSA are shown in Figure 3.5 and Table 3.2, 
respectively. Aqueous medium in the samples was refreshed through two different 
pathways: i) after 1, 2, 3 and 4 hours of incubation (dashed curve in Figure 3.5), ii) 
after 72, 73 and 74 hours of incubation. According to Figure 3.5, the overall three-day 
release of post-encapsulated protein from (Dex/PAr)3 and (Alg/PAr)3 microcapsules 
was nearly 84 % and 28 % ,respectively. For comparison, ‘pre-loaded’ (Dex/PAr)3 
and (Alg/PAr)3 microcapsules released correspondingly 9 % and 6 % of their content 
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at similar order of medium refreshment. The release rate data (Table 3.2) indicated 
that the ‘post-loaded’ capsules, on average, released TRITC-BSA twice as fast at 
hourly medium exchange and 3 times faster over 72 hours of incubation without 
medium refreshment than ‘pre-loaded’ formulations. 
 
Figure 3.5. Release of TRITC-BSA ‘post loaded’ into PEL multilayer microcapsules 
composed of (Dex/PAr)3 (-□- and -■- (a)) and (Alg/PAr)3 (-○- and -●- (b)). Open 
symbols correspond to data recorded after 1, 2, 3, 4 and 76 hours of incubation, closed 
symbols related to protein release measured after 72, 73, 74 and 75 hours of 
incubation. Aqueous medium in the samples (V = 1 ml, 0.15 M NaCl, T = +37 C.) 
was fully refreshed at each time point. 
 
Our results showed that Dex/PAr capsules released TRITC-BSA faster than 
Alg/PAr ones, when medium refreshment was performed every 24 hours or less 
frequently. On the contrary, when medium refreshment was done hourly, Alg-based 
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formulation liberated the protein 2 times faster regardless of loading routine. The 
possible reason for this observation is that frequent medium refreshment facilitates 
desorption of molecules from outer layers of capsules’ shell and also with the fact that 
Alg/PAr membrane encapsulated higher amount of TRITC-BSA in comparison with 
that fabricated of Dex/PAr. With less medium refreshment, desorption of protein 
molecules from Dex/PAr complex preceded faster than in Alg gel. 
Less retentive shells assembled from (Dex/PAr)3 released approximately 50 % 
of encapsulated TRITC-BSA over 72 hours into 1 ml of 0.15 M NaCl, indicating the 
achieved equilibrium between protein contained in the bunch of microcapsules and 
those appeared in the surrounding aqueous media. Since the concentration of TRITC-
BSA in one capsule remained sufficiently high (about 18 mg/ml), the release would 
continue even if the aqueous medium was not refreshed. Similar to those in Figure 3.4, 
the release curves in Figure 3.5 display the same slopes in the regions corresponding 
to non-disturbed incubation over 72 hours, and TRITC-BSA release over 3 hours with 
hourly medium refreshment. Depending on shell composition, the ‘post-loaded’ 
capsules released 15 % - 25 % of their content over the first 4 hours with hourly 
medium refreshment, resulting in substantial decrease in protein concentration in 
individual capsule. Although similar to ‘pre-loaded’ capsules, their subsequent release 
did not slow down. 
 
3.3.5 The mechanism of protein accumulation and release 
According to our data, the main factor which determines the rate of TRITC-
BSA release from investigated microcapsules is the kinetics of protein adsorption by 
the capsule shell and its subsequent release into surrounding medium. Generally, a 
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rather dense polymer network in the capsule’s shell serves as a mechanical barrier for 
the release of encapsulated protein molecules. At the same time, the presence of 
uncompensated electric charges within PEL multilayers together with gel-like 
morphology of Alg/PAr complex, lead to protein trapping and accumulation in the 
shell due to electrostatic interactions. As a result, fouling of capsule membrane occurs 
and membrane permeability decreases. During CaCO3 core dissolution, the release of 
‘pre-loaded’ protein molecules are driven by high concentration gradient across 
capsule shell and an increased permeability of PEL multilayers induced by pH and 
salt concentration change.
22-24
 Protein/multilayer shell interactions result in 
entrapment of macromolecules within PEL network. Figure 3.6 shows schematic 
representation of TRITC-BSA distribution across the capsule shell. Diffusing from 
inside to outside of the capsule, the protein molecules in ‘pre-loading’ process are 
being trapped mostly on the inner surface of the membrane and in between the inner 
polymer layers (Figure 3.6 left panel). In contrast, in the ‘post-loading’ process, 
molecules’ diffusion is directed towards the center of the capsule. Hence, they 
accumulate mostly on and in between the outmost layers of the shell (Figure 3.6 right 
panel). Faster release rate of ‘post-loaded’ TRITC-BSA from PEL microcapsules is 
possibly due to liberation of protein molecules trapped close to outer surface. In the 
case of ‘pre-loaded’ capsules, a considerable quantity of TRITC-BSA molecules are 
located in the inner part of the shell and cannot diffuse easily out of the capsules. 

















Figure 3.6. Schematic representation of TRITC-BSA distribution across the capsule 
shell during CaCO3 template dissolution (left panel) and protein ‘post-loading’ into 
PEL multilayer microcapsules (right panel). x is a space axis across the capsule shell. 
 
Membrane fouling is a common phenomenon, for instance, in filtration system, 
where the flux of the membrane decreased quickly within a few hours before reaching 
a steady state.
24-27
 Similar effect of entrapment of low and high molecular weight 
compounds (fluorescein, fluorescein isothiocyanate labeled dextrans of Mw = 2 × 10
6
 
g/mol, Mw = 2.6 × 10
5
 g/mol, Mw = 7.7 × 10
4
 g/mol and Mw = 4.4 × 10
3
 g/mol) added 
to surrounding aqueous medium was reported in CT/chitosan sulfate microcapsules 
templated on acid-soluble melamine formaldehyde particles and proved to be resulted 
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To verify the postulated phenomenon of protein accumulation within the 
capsule wall, (Dex/PAr)3 and (Alg/PAr)3 capsules were examined by SEM (Figure 
3.7). In Figure 3.7, comparison is made between two different shell compositions and 
between the empty and protein-loaded capsules, respectively. SEM images of 
(Dex/PAr)3 and (Alg/PAr)3 capsules ‘post-loaded’ with TRITC-BSA were taken after 
72 hours long incubation in 1 ml of 0.15 M NaCl solution. The shells of empty 
(Dex/PAr)3 and (Alg/PAr)3 capsules looked clearly different on the patterns a1 and b1 
in Figure 3.7. The Alg-based composition is visibly thicker and characterized by more 
even surface than Dex/PAr one. The SEM image of (Dex/PAr)3 capsules was similar 
to that observed for PSS/PAH shells.
8
 Protein-loaded capsules of each investigated 
composition exhibit significantly increased thickness in comparison with empty ones 
due to the presence of coupled BSA molecules. (Figure 3.7, a2 and b2) 
 
Figure 3.7. SEM images of microcapsules composed of (Dex/PAr)3 (a) and 
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(Alg/PAr)3 (b). Empty capsules (a1, b1), capsules loaded with TRITC-BSA (a2, b2). 
 
CLSM images illustrating the distribution of “postloaded”TRITC-BSA 
within (Dex/PAr)3 and (Alg/PAr)3 capsules are shown in Figure 3.8. It can be seen 
that the protein molecules penetrated inside the interior of microcapsules leave a 
certain fraction entrapped within the multilayer shell. The comparative amount of 
entrapped protein was found to be sufficiently higher in the case of (Alg/PAr)3 
microcapsules, which displayed visibly brighter edges than interior (Figure 3.8b). 
 
Figure 3.8. CLSM images of microcapsules “postloaded” with TRITC-BSA. Shell 
design: (a) (Dex/PAr)3 and (b) (Alg/PAr)3 
 
3.4 Conclusions 
In this paper, we examined multilayer PEL capsules as a system for control 
release of protein drug. Based on observed difference in release of TRITC-BSA upon 
varying the capsule shell composition and thickness, loading routine and 
concentration difference across capsule membrane, we reveal the mechanism of the 
release process. The key phenomenon determining the protein release is the property 
of multilayer PEL shells relating to the entrapment and accumulation of protein 
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molecules. Protein accumulation in the capsule shell occurs during release of ‘pre-
loaded’ macromolecules or during their infiltration into pre-formed hollow capsules. 
Regardless of the protein encapsulation approach, being either ‘pre-loading’ in co-
precipitating CaCO3 particles or ‘post-loading’, capsule’s shell composition and 
thickness have incremental effect on the amount of encapsulated protein molecules. 
Alg present in capsule membrane provides larger capacity for protein accumulation as 
compared to Dex. Hence, better protein entrapping capability of Alg/PAr multileyers 
was observed during co-precipitated CaCO3 dissolution as well as during ‘post-
loading’ of hollow capsules with TRITC-BSA. At the same time, ‘post-loaded’ 
microcapsules of each investigated composition released protein faster than ‘pre-
loaded’ ones, as a result of the proposed different mechanism of protein distribution 
across the capsule shell. 
The investigated capsules released their encapsulated protein quite slowly and 
with external protein consumption, release of more protein is facilitated by desorption 
of protein molecules entrapped in the outer layers of the capsule shell. We 
demonstrated the possibility to influence the rate of protein release from microcapsule 
via varying thickness and composition of its shell. Hence, the loaded PEL multilayer 
capsules can be customized to sustain release proteins (macromolecules) in pre-
defined concentration. TRITC-BSA release from Dex/PAr and Alg/PAr 
microcapsules has zero-order kinetics at some investigated conditions, e.g. with 
hourly medium refreshment. Our results have demonstrated the potential of PEL 
microcapsules as promising candidates for control release of drugs with narrow 
therapeutic range, for instance, basic fibroblast growth factor. 
PEL capsules can be likened as hydrogels in their ability to accumulate 
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macromolecules within shells. But, unlike hydrogel, the main advantage of 
microcapsules (or any micro-vehicle with top coating) as a system for controlled 
release is the potential to fine-tune the release rate by simple means of shell design. 
The control over release of incorporated molecules can be achieved by varying the 
selection of available polymers in combination with thickness of assembled multilayer 
coating shell. 
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4.1 Introduction  
Wound healing is an intricate and self-repairing process triggered immediately 
after injury by releasing various cytokines, and low-molecular-weight compounds 
from the blood serum and degranulating platelets at wound sites.
1
 Basic fibroblast 
growth factor (FGF2, 17.2 kDa) is one of such essential mitogenic cytokine proteins 
for early stages wound healing. FGF2 stimulates growth and proliferation of 
fibroblasts as well as capillary endothelial cells, and enhances tissue regeneration and 
angiogenesis which are very important for wound healing.
2-5
 It also regulates other 
aspects of cellular activity, such as cell migration and extracellular matrix metabolism. 




FGF2 can be synthesized and secreted by many spicies such e.coli. whereas 
this work is done by human adipocytes in human body.
7
 Upon releasing from the cell, 
FGF2 will bind to heparan sulfate proteoglycans in extracellular matrix. Then it can 
be mobilized by heparinase and released in the form of complexation with heparan 
sulfate.
8
 It is noteworthy that the formation of complex with heparin or heparan 
sulfate proteoglycans is essential for the activation of the FGF2 signaling receptors.
8,9
 
After diffusing away from the matrix, this complex is capble of binding to the high 




FGF2 exhibits its optimal proliferative efficacy within a certain concentration 
range. For example, maximal rate of proliferation of periodontal ligament cells has 
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been observed at FGF2 concentration ranging from 10 to 100 ng/ml.
11
 However, 
FGF2 is highly vulnerable to environmental factors, especially temperature and pH. It 
degrades rapidly if surrounding temperature is above 40 
o
C or pH is less than 5.
12
 
When injected in soluble form into a human body, efficacy of FGF2 is limited 
because of short retention time at wound sites and short half-life caused by diffusion 
and susceptibility to enzymatic degradation.
13,14
 Therefore, a suitable delivery system 
that can protect and release FGF2 in a sustained and controlled manner is demanded. 
Currently available FGF2 delivery systems often suffer from poor control of 
the capsule size and protein release rate, high denaturation of the protein during the 
capsule fabrication, and low loading efficiency. A number of PEL materials, for 
instance, CT/GL microspheres and Alg based hydrogels have been employed for 
encapsulation and controlled release of FGF2.
15,16
 These hydrogel capsules seldom 
fulfill all criteria of a successful delivery system, such as precise control of the 
capsule size and protein release rate, low denaturation of the protein during the 
capsule fabrication, and high loading efficiency. PEL multilayer microcapsules have 
been versatile and multifunctional carriers for macromolecules.
17,18
 A variety of 
loading routines have been developed for effective encapsulation of different active 
compounds.
19
 Layer by Layer (LbL) encapsulation technology is also one of the most 
suitable and simplest methods to prepare microcapsules with tunable permeability by 
varying their composition and thickness.
20
 
pH is a well known trigger to increase permeability of PEL multilayer 
capsules.
21-24
 Itoh et al. prepared microcapsules via LbL assembly of CT and Dex, and 
demonstrated post-loading of FGF2 at pH 8 where the CT/Dex multilayers had a 
relatively high permeability for the protein.
20
 Recently, post-loading of transforming 
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growth factor-1 (TGF-1) into heparin/PAr microcapsules with pre-loaded heparin 
was reported. These microcapsules could successfully maintain the bioactivity of 
TGF-1 and stimulate myofibroblast differentiation and contraction in vitro.26 We 
previously employed a protein pre-loading routine based on porous inorganic micron-
sized spherical templates pre-saturated with the protein molecules followed by 
multilayer shell assembly and core extraction.
27-29
 This method has been proven to 




Herein, we propose to use the pre-loading routine for FGF2 encapsulation in 
order to achieve its sustained and controlled release for stimulating cell growth and 
proliferation. Another key issue in encapsulating and delivering FGF2 is to protect 
and maintain its biological activity. Therefore, we have co-encapsulated FGF2 with 
heparin, which is known to bind FGF2 and can maintain about 80% bioacitivity of 
FGF2 for two days at 37 C. Under the same conditions, FGF2 can only maintain less 
than 10% bioactivity if there is no heprarin protection.
3
 In this report, we have 
investigated the pre-loading routine for efficient encapsulating FGF2, and the co-
encapsulating heparin for keeping the bioactive of FGF2. We measured the 
cytotoxicity of the microcapsules, and obtained the FGF2 release profiles from the 
microcapsules. Finally we performed a comparative study of the LbL microcapsule 
FGF2 delivery system and free FGF2 in terms of the effect on proliferation of L929 
cells. 
4.2 Experimental Section  
4.2.1. Materials 
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All reagents were used as received without further purification. Dex (MW > 
500000), PAr (MW > 70000), BSA, heparin (sodium salt from porcine intestinal 
mucosa), flourescein isothiocyanate bovine serum albumin (FITC-BSA), Dulbecco's 
phosphate-buffered saline (DPBS), penicillin, streptomycin, CaCl2, Na2CO3, NaCl, 
4’,6-diamidino-2-phenylindole dihydrochloride (DAPI), ethylenediaminetetraacetic 
acid trisodium salt (EDTA), penicillin and streptomycin (PS) were obtained from 
Sigma-Aldrich. The recombinant human FGF2 (purity > 95%) and Quantikine Human 
FGF basic Immunoassay kits were purchased from R&D systems. CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay kits that contains 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt, (MTS) and phenazine methosulfate (PMS) were purchased from Promega. 
Dulbecco's modified eagle's medium (DMEM) and fetal bovine serum (FBS) were 
obtained from Invitrogen. L929 mouse fibroblast cell line was obtained from 
American Type Culture Collection (ATCC, Rockville, MD, USA). Deionized water 
with specific resistivity higher than 18.2 MΩ·cm from a three-stage Milli-Q Plus 185 
purification system was used in the experiments. 
 
4.2.2 Loading of FGF2 into PEL multilayer microcapsules 
To obtain a stock solution, lyophilized powder of FGF2 was reconstituted with 
DPBS buffer containing heparin and BSA to reach the final concentration of 100 
g/ml for FGF2 and a weight ratio of BSA : heparin : FGF2 at 10: 10: 1. DPBS was 
used for further dilution. The PEL multilayer microcapsule was formed by pre-
loading routine and LbL process described in previous chapters. Briefly, the FGF2 
stock solution (1.0 ml) was mixed under vigorous agitation with 1.0 ml of DI water, 
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1.0 ml of 1.0 M CaCl2 solution and 1.0 ml of 1.0 M Na2CO3 solution (all solutions 
were sterilized by filtration with 0.2 m filter). The process resulted in formation of 
protein-loaded CaCO3/FGF2 microparticles. Negatively charged Dex and positively 
charged PAr were selected as shell constituents because of their biodegradability and 
good mechanical stability of formed microcapsules due to tight complexation of the 
biopolymers.
30,31
 After the desired number of PEL layers in the shell was achieved, 
CaCO3 template was dissolved by three consecutive treatments with 0.2 M EDTA 
(pH = 7.0) lasting for 30 min each. The obtained protein-loaded microcapsules were 
then washed two times with serum-free DMEM. By this routine, microcapsules 
comprising 6, 10 and 14 PEL layers were prepared and stored in a form of aqueous 
suspension at 4 
o
C if necessary. Supernatants obtained on each stage of the 
encapsulation process were collected for further analysis of the FGF2 concentration. 
The EE of FGF2 was calculated as (mI – (mS1 + mS2 + …+ mSn))/mI100%, where mI 
is the initial amount of FGF2 used in the process of CaCO3 synthesis, and mS is the 
amount of FGF2 in a supernatant. 
The same protocol was followed for FITC-BSA loading into PEL multilayer 
capsules. Initial amount of FITC-BSA in 1.0 ml of an aqueous solution used for 
CaCO3/FITC-BSA particle synthesis was 1.0 mg. 
 
4.2.3. Microcapsule counting 
The amount of capsules was determined by a hemacytometer. Two units, 
“capsules per ml” (c/ml) and “capsules per cell” (c/c) were used in the manuscript to 
refer to the capsule concentration in a sample. The amount of capsules in 1.0 ml of 
liquid comes directly from counting, and the conversion relationship between the 




 c/ml = 100 c/c considering the protocol of cell culture used in our 
experiments (described below). The routine of capsule synthesis described above 
usually resulted in approximately 9.0108 capsules in the whole batch. 
 
4.2.4. FGF2 concentration measurements 
To minimize the loss of FGF2 caused by its adsorption onto the walls of test 
tubes and cell culture plates, the surfaces were passivated by BSA soaking overnight 
in 1.0 mg/ml protein solution. The Quantikine Human FGF basic Immunoassay kit 
(96 wells) was used to measure the FGF2 concentration in the samples. The 
Quantikine kit employs the enzyme-linked immunosorbent assay (ELISA), which is a 
widely accepted method for quantitative detection of the bioactive FGF2.
3
 In brief, 
standards and samples were pipetted into the microplate wells pre-coated with a 
monoclonal antibody specific for FGF2, and any FGF2 present was bound by the 
immobilized antibody. After washing away any unbound substances, an enzyme-
linked monoclonal antibody specific for FGF2 was added to the wells. Following a 
wash to remove any unbound antibody-enzyme reagent, a substrate solution was 
added to the wells and color developed in proportion to the amount of FGF2 bound in 
the initial step. Absorbance was read at 450 nm by a microplate reader (TECAN 
Spectrafluor Plus) with background subtraction at 570 nm. All data represented the 
mean of three measurements of three different trials, and results were reported as the 
means and standard deviations of these measurements. 
 
4.2.5. FGF2 release profile measurements 
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Measurements of FGF2 release profiles were carried out in 96-well plates. 
DMEM medium (200 l ) containing 5 % FBS was added to each test well on the first 
day. On the second day, the medium was refreshed by serum-free DMEM and FGF2-
loaded microcapsules were added. Supernatants were collected daily starting from the 
day when the microcapsules were added (day 0, blank medium) to the third day of 
incubation (day 3). The FGF2 concentrations in supernatants were measured by the 
Quantikine kit. All measurements were performed in triplicate. 
 
4.2.6. Cell culture studies 
L929 mouse fibroblast cell line was used to study the effect of the PEL 
multilayer encapsulation on FGF2 delivery. The cells were incubated in 75 cm
2
 tissue 
culture flasks at 37 C in a humidified atmosphere of 5% CO2 and 95% air incubator 
before seeding in cell culture plates for further in vitro experiments. The cell culture 
medium consisted of DMEM with 10 % FBS and the PS (50U/ml & 0.05mg/ml). 
To ensure cell proliferation is not affected by the space and nutrition 
limitations, we performed a set of screening tests to determine the optimal conditions 
for cell culture: the cell density was 5000 cells per well in a 96-well plate; the volume 
of the medium was 200 l; experiment duration without medium refreshment was 3 
days. To attenuate the denaturing rate of free FGF2 at 37 
o
C, heparin was added to the 
cell culture medium in the weight ratio of heparin: FGF2 = 10: 1. 
For the purpose of attachment, L929 cells were seeded in wells filled with 5% 
FBS DMEM. One day after (day 1), the medium was replaced with serum-free 
DMEM and tested dispersions of microcapsules or FGF2 solutions were added. The 
effect of FGF2 on cell proliferation was evaluated three days later (day 3) using 
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the calorimetric MTS assay designed to measure the activity of a dehydrogenase 
enzyme in metabolically active cells. The absorbance corresponding to the amount of 
active cells was measured at 492 nm by a microplate reader. 
 
4.2.6. Optical microscopy 
FGF2 induced changes in cell morphology were observed by Olympus IX51 
microscope equipped with 20X objective lens in a bright field mode. Images were 
captured at 3 different sites of each sample, and the ratio of the cells with apparent 
morphology changes to the cells with intact morphology was calculated. 
 
4.2.7. Tracking of microcapsules by CLSM 
FITC-BSA loaded microcapsules were incubated with L929 cells in a glass 
base dish. The cells were washed twice with DPBS buffer after one day incubation to 
remove free microcapsules that were not internalized by cells. Then the cells were 
fixed in 4% paraformaldehyde for 15 minutes and cell nuclear were stained with 
DAPI for 5 minutes before CLSM measurements. Images were obtained on a Carl 
Zeiss Lsm510 META CLSM system (Carl Zeiss AG, Germany) equipped with a C-
Apochromat 63X/1.2 Water Lens objective. The excitation wavelength λex = 488 nm 
and emission wavelength λem = 525 nm were used for scanning of FITC-BSA, while 
λex = 405 nm and λem. = 430 nm were used for DAPI. The depth scanning mode along 
Z-axis had a resolution of 0.7 m/layer, and the pinhole size was 140 µm. 
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4.3 Results and Discussion 
4.3.1. FGF2 encapsulation 
Being sensitive to the environmental conditions, FGF2 loses its bioactivity if 
there is no proper protection.
3
 In our experiments, FGF2 lost the bioactivity almost 
completely during the CaCO3-assisted encapsulation process, probably due to 
prolonged exposure to room temperature (more than 3 hours), interaction with Ca
2+
 
cations and components of cell culture medium, and substantial pH change caused by 
Na2CO3. In order to minimize FGF2 denaturation, a buffer solution containing 
heparin and BSA was used as the aqueous medium for synthesis of FGF2/CaCO3 
microparticles. To verify the bioactivity of the incorporated FGF2, FGF2/CaCO3 
microparticles were treated with 0.2 M EDTA (pH 7.4), and then the FGF2 
concentration in the solution after CaCO3 decomposition was examined with the 
Quantikine kit. Our measurements revealed that the loss of FGF2 bioactivity upon 
CaCO3 microparticle synthesis did not exceed 5%.  
Table 4.1 summarizes the main parameters during the loading and 
encapsulation of FGF2 into the Dex/PAr microcapsules of different thicknesses. The 
efficiency of the FGF2 loading into the CaCO3 microparticles was 68%. The amount 
of recovered FGF2 in the supernatants collected after adsorption of each shell layer 
and upon particle washings indicates a moderate loss of pre-loaded FGF2 in the 
process of multilayer shell assembly, and it was in inverse relation with the number of 
layers adsorbed. For instance, deposition of the first polymer layer resulted in a loss of 
9.6 g of FGF2, while only 0.1 g was lost during deposition of the 5th layer. The loss 
of FGF2 became negligible after the deposition of the 6
th
 shell layer (Figure 4.1). Our 
results showed that 53% of the initial amount of FGF2 was encapsulated in the 
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FGF2/CaCO3 core-shell microparticles (Table 4.1). 
 




























6 100  68.0 ± 2.4 53.9 ± 2.0
c
 29.4 ± 5.0 29.4 ± 5.0 
10 100  68.0 ± 2.4 
d 
35.9 ± 4.2 36.9 ± 4.2 
14 100  68.0 ± 2.4 
e 
42.4 ± 4.6 42.4 ± 4.6 
a
 Initial amount of FGF2 was calculated based on dilution rate of the stock solution. 
b
 Measured by 
Quantikine Kit from three samples. Capsules of different layers used the same batches of CaCO3cores. 
c
 Measured by Quantikine Kit for 6-layer Dex/Par capsules from three samples. 
d,e
 From layer 6 the loss 
of FGF2 was negligible (Figure 1), so FGF2 in the 10-layer and 14-layer core-shell microparticles 
could be considered the same as that of 6 layer (54 g). f Measured by Quantikine Kit from three 
samples. 
g




Figure 4.1. Cumulative loss of FGF2 during the multilayer shell assembly. 
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Extraction of the CaCO3 template by EDTA caused burst release of a major 
fraction of the incorporated protein. The rate of the burst release could be controlled 
by the thickness of the PEL shell.
20
 In this study, capsules coated with the thicker 
shells lost less amount of FGF2 in the process of CaCO3 dissolution (Table 4.1). For 
instance, the capsules with the shell comprising 14 PEL layers retained 42% FGF2, 
which was 13% more than those comprising 6 layers. The FGF2 EE of this method 
(42%) is higher than that based on CT NPs (27 %) reported earlier.
27
 In another report, 





4.3.2. Optimal concentration range of FGF2 for L929 cell proliferation 
To determine the optimal concentration range of FGF2, L929 cells were 
cultured in the medium with different concentrations of free FGF2. The results of the 
MTS assay performed after three days of cell culture are shown in Figure 4.2. The 
rate of cell proliferation reached maximum at the FGF2 concentrations ranging from 
10 to 100 ng/ml, where the cell number increased by about 50% with respect to the 
control group of cells cultured without FGF2 (Figure 4.2). A similar optimal 
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Figure 4.2. Effect of free FGF2 on proliferation of L929 cells. 
 
4.3.3. Cytotoxicity of Dex/PAr microcapsules 
For cytotoxicity studies, L929 cells were cultured for three days in the 
presence of hollow Dex/PAr microcapsules of different thicknesses. The results 
shown in Figure 4.3 suggest that the microcapsules had low cytotoxicity at 
concentrations lower than 50 c/c. Above this concentration, cell viability dropped 
below 80%, indicating a considerable negative effect of the capsules on cell 
proliferation. Importantly, the shell thickness had a negligible impact on the capsule 
cytotoxicity. 
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Figure 4.3. Cell number after three days of culturing in serum-free DMEM in the 
presence of hollow Dex/PAr capsules comprising 3 bilayers (--), 5 bilayers (--), 
and 7 bilayers (--). 
 
4.3.4. In vitro release kinetics of FGF2 from Dex/Par microcapsules 
We reported that the kinetics of protein (BSA) release from the PEL 
multilayer microcapsules depended on the capsule thickness and concentration.
21
 
Therefore, we could achieve release profiles that match the optimal FGF2 
concentration range by varying of the capsule thickness and concentration. We first 
measured the release profiles for capsules composed of 3, 5, and 7 Dex/PAr bilayers 
at 7.5105 c/ml (equivalent to 30 c/c in our cell culture protocol), which showed 
negligible cytotoxicity (Figure 4.4a). The FGF2 release was performed into serum-
free DMEM. The supernatants were collected daily from day 0 (blank medium) to day 
3 and then the FGF2 concentrations were measured by the Quantikine kit. The FGF2 
concentration reached maximum levels for (Dex/PAr)3 microcapsules on day 1, and 
for (Dex/PAr)5 and (Dex/PAr)7 microcapsules on day 2, after which the FGF2 
concentration decreased. On day 3, Dex/PAr microcapsules with thicker 
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shells maintained higher FGF2 concentrations than those with thinner shells. FGF2 
was protected by heparin in our experiments.  
 
Figure 4.4. In vitro release of FGF2 from (Dex/PAr)3 (--), (Dex/PAr)5 (--), and 
(Dex/PAr)7 (--) microcapsules into 200 l of serum-free DMEM at 37 
o
C. (a) 
Capsule number: 1.5105; Concentration of capsules: 7.5105 c/ml (or 30 c/c), 
equivalent to total FGF2 concentrations of 24, 30, and 35 ng/ml for (Dex/PAr)3, 
(Dex/PAr)5, and (Dex/PAr)7, respectively. (b) Capsule number: 510
5
; Concentration 
of capsules: 2.5106 c/ml (or 100 c/c), equivalent to total FGF2 concentrations of 80, 
100, and 117 ng/ml for (Dex/PAr)3, (Dex/PAr)5, and (Dex/PAr)7, respectively.  
 
The main concern about the release profiles in Figure 4.4a, was the very low 
detected bioactive FGF2 concentrations in the medium. In attempt to match the 
optimal FGF2 concentrations, we increased the amount of the capsules to 100 c/c 









 Chapter 4: Encapsulation of FGF2 
 91 
Figure 4.4a, and only (Dex/PAr)7 capsules could achieve the optimal FGF2 
concentrations for L929 cell proliferation. 
 
4.3.5. Controlled release of FGF2 from Dex/PAr microcapsules for enhancing 
L929 cell proliferation 
To figure out whether the controlled release of FGF2 by PEL microcapsules 
has advantages over the free FGF2 on L929 cell proliferation, L929 cells were 
cultured in the presence of FGF2-loaded (Dex/PAr)3, (Dex/PAr)5 and (Dex/PAr)7 
microcapsules with concentrations falling into the range of acceptable cytotoxocity 
(from 1 c/c to 100 c/c). Cell numbers after 3 days of incubation with FGF2-loaded 
microcapsules were measured in respect to a control with L929 cells cultured in the 
medium containing 10 ng/ml of free FGF2 (control group), which is the optimal 
condition for L929 cell proliferation without a controlled release system. Despite the 
release profiles, the results showed that the microcapsules were capable to promote 
L929 cell proliferation at capsule concentrations ranging from 5 to 30 c/c, providing 
10 - 30% increase in cell number after three days of culture (Figure 4.5a). At the same 
time, we did not observe any significant difference between the microcapsules of 
different thicknesses. 
We also plot the relative proliferation of L929 cells after 3 days culture with 
free FGF2 (10 ng/ml), hollow (Dex/PAr)3 capsules (10 c/c), and FGF2 loaded 
(Dex/PAr)3 capsules (10 c/c). Here the relative cell numbers are calculated with 
respect to the control group with cells cultured in DMEM without addition of any 
FGF2 or capsules (Figure 4.5b). While the free FGF2 resulted in 150% cell 
proliferation, FGF2 loaded (Dex/PAr)3 capsules could further increase the cell 
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proliferation up to nearly 200%. The group with addition of hollow capsules showed 
nearly the same cell proliferation rate as the control group, indicating that the 
cytotoxicity of the hollow capsules could be negligible. 
 
Figure 4.5. (a) Relative numbers of L929 cells after 3 days culture with FGF2-loaded 
capsules of different concentrations and shell thicknesses (Dex/PAr)3 (--), 
(Dex/PAr)5 (--), (Dex/PAr)7 (--) with respect to the control with 10 ng/ml of free 
FGF2. (as relative cell number 100%); **: P < 0.05 (from 2-tail student t-test), 
indicates significant difference from control group. (b) Relative numbers of L929 
cells after 3 days culture with free FGF2 (10 ng/ml), hollow (Dex/PAr)3 capsules (10 
c/c), and FGF2 loaded (Dex/PAr)3 capsules (10 c/c) with respect to the control group 
(as relative cell number 100%) with cells cultured in DMEM without addition of 
FGF2 or capsules. 
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Another evidence of effective controlled release of FGF2 by the PEL 
multilayer microcapsules was obtained by investigating the cell morphology (Figure 
4.6). Although FGF2 is thought to be the most important protein to promote mitotic 
activity and cell proliferation, it is also known to suppress synthesis of collagen I and 
III, causing an abnormal cell morphology.
33-35
 We found that over 80% of L929 cells 
in a batch turned round after 2 days of culture in the medium containing 10 ng/ml of 
free FGF2. Similar result was obtained for a group of cells incubated with 5 - 30 c/c 
FGF2-loaded Dex/PAr microcapsules, while less than 5% of cells exhibited the 
abnormal spherical morphology in a control group cultured in serum-free DMEM or 
in the presence of hollow Dex/PAr microcapsules. 
 
 
Figure 4.6. Cell morphologies after two days of culture in the presence of 10 ng/ml of 
free FGF2 (ca 84% of spherical cells) (a), in serum-free DMEM (ca 2% of spherical 
cells) (b), in the presence of FGF2-loaded (Dex/PAr)3 capsules (5 c/c) (ca 82% of 
spherical cells) (c), and in the presence of hollow (Dex/PAr)3 capsules (ca 1% of 
spherical cells) (d). The percentages of cells with spherical morphology are the 
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average from three different wells. 
 
Although the FGF2 concentration levels in the microcapsules controlled 
release systems were lower than those optimal FGF2 concentrations for L929 cell 
proliferation in free FGF2 systems, the controlled released systems resulted in 10 - 
30% higher cell proliferation rate after three days of culture (Figure 4.5). The possible 
reason may be the protection of FGF2 that were stored in the interior of the PEL 
multilayer shells, and each portion of released FGF2 was absorbed by the cells before 
its degradation. In order to verify this assumption, we measured the concentrations of 
free and encapsulated FGF2 in the medium with and without cells, and then calculated 
the amounts of bioactive FGF2 in the total volume of the medium in a well (200 l) 
(Figure 4.7). The difference of the areas under the curve measured without cells and 
that with cells can be considered to be the amount of FGF2 absorbed by the cells. The 
total absorbed FGF2 amount in the (Dex/PAr)7 capsule system was five times higher 
than the free FGF2 system. Therefore, the use of PEL microcapsules for FGF2 release 
could reduce the overall amount of FGF2 needed in the cell culture providing the 
same or even higher rate of cell proliferation. For the optimal cell proliferation, free 
FGF2 system required higher FGF2 dosages (2 – 20 ng), while the microcapsule 
controlled release systems required much less FGF2 dosages (0.8 - 4.8 ng for 
(Dex/PAr)3, 1.0 – 6.0 ng for (Dex/PAr)5, and 1.2-7.0 ng for (Dex/PAr)7).  
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Figure 4.7. Amounts of bioactive FGF2 detected in DMEM medium upon incubation 
at 37 C: free FGF2 without cells (--) and with cells (--); and (Dex/PAr)7 
encapsulated FGF2 without cells (-●-) and with cells (-■-) (capsules concentration: 
30 c/c). 
 
Another possible reason for the enhancement of cell proliferation by the 
encapsulated FGF2 release could be high affinity of the PEL microcapsules to the cell 
surface. Figure 4.8 displays CLSM images of cells in the presence of Dex/PAr 
microcapsules loaded with fluorescence labeled BSA (FITC-BSA). It can be seen that 
the microcapsules could attach onto the cell surface (Figure 4.8 a, b). As mentioned in 
the introduction, FGF2 needs to bind receptors on the surface of cell membrane in 
order to activate phosphoinositide 3-kinase.
10
 Now, FGF2 can immediately bind to the 
receptor once it is released due to the attachment of FGF2 loaded microcapsules onto 
the cell surface. And this kind of ‘use-upon-release’ feature can reduce the chance of 
FGF2 degradation both in vitro and in vivo. This feature of the PEL microcapsules 
may also become especially advantageous in vivo, since free FGF2 has very short 
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retention time at the wound site due to fast diffusion and enzymatic degradation.
36
 
Because of high affinity to the cell surface, the microcapsules are expected to create 
higher local concentration of FGF2 at the wound site enabling more effective 
utilization of FGF2 by the cells. Furthermore, from the 3D information provided in 
Figure 4.8a and 4.8c, a few microcapsules were found to be internalized by cells. 
Although it is thought that microparticles with size over 1 micrometer to be 
internalized by cells from the traditional point of view, more and more papers have 
observed cellular uptake of microsize particles in various cell types such as breast 
cancer cells, hepatoma cells, fibroblasts and epithelial kidney cells.
37
 Our result 
confirms the phenomenon again. However, the uptake mechanism is not well 
understood based on current studies. The cellular uptake ability may not be so 
important in FGF2 delivery because FGF2 only binds to receptors on the cell 
membrane, but it is desirable for gene and anti-cancer drug delivery. Moreover, the 
uniform distribution of fluorescent intensity aross the whole cytoplasm of some cells 
may indicate the enzymatic erosion or degradation of PEL microcapsules by the cell. 
The biodegradability guarantees fast clearance of carrier from body and then 
negligible long-term toxicity. 
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Figure 4.8. CLSM images of L929 cells incubated with FITC-BSA-loaded 
(Dex/PAr)3 microcapsules: (a) Cross section fluorescence image with z-axis 
fluorescence projection at the cross-plane displayed (windows at the bottom and on 
the right), scale-bar: 20 m; (b) Overlap of fluorescence mode and bright field mode, 
scale-bar: 20 m; and (c) 3D fluorescence image from the top view, frame length and 
width: 210 m; height: 13 m. 
 
Although FGF2 is essential to promote cell growth, we observed that the 
number of cells cultured in 10% FBS with no extra FGF2 added can reach almost 
200% proliferation rate as compared to the control group of cells cultured in the 
medium containing 10 ng/ml of free FGF2. It was found that the 10% FBS medium 
contained only about 8 pg/ml of FGF2, indicating that other actives and compounds in 
the medium are also important for the cell proliferation. Indeed, in addition to FGF2, 
a number of growth factors regulating cell division and cell survival can be found in 
human serum, including insulin-like growth factor, platelet-derived growth factor, 
epidermal growth factor, and TGF-. The CaCO3 pre-saturation routine may enable 
simultaneous loading of different growth factors into the PEL multilayer 
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microcapsules, and the release multiple growth factors from the microcapsules may be 
promising for would healing therapies. For example, it was reported that normal 
extra-cellular matrix formation is essential for scar-free wound healing. Release of 
platelet-derived growth factor and TGF- can promote the normal extra-cellular 
matrix formation.
33-35 
Future studies may also involve protection of FGF2 against the 




PEL multilayer microcapsules were employed for controlled release of FGF2 
in vitro. Since FGF2 is highly vulnerable to the environmental conditions, such as 
temperature, pH, salinity and enzymes, special attention was given to maintain its 
bioactive form upon encapsulation and release. Encapsulation of FGF2 into Dex/PAr 
shells of different thicknesses was performed by pre-loading of the protein into porous 
CaCO3 microparticles followed by shell assembly and extraction of the inorganic 
template. Heparin and BSA were simultaneously loaded into the microcapsules and 
proved to protect the bioactivity of FGF2 at each stage of the encapsulation process 
and upon storage inside the capsules. 
The Dex/PAr microcapsules were low cytotoxic for L929 cell line and capable 
to sustain release of the incorporated protein. The FGF2 release rate was finely 
adjusted by changing the thickness of the microcapsules.  
The controlled release of FGF2 from the microcapsules was advantageous to 
enhance the proliferation of L929 cells over the system with free FGF2. In particular, 
the controlled release systems required much lower FGF2 concentration for achieving 
even higher cell proliferation rate than the free FGF2 system. Presumably, good 
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protection of FGF2 in the interior of the PEL multilayer shells and high affinity of the 
microcapsules to the cell surface facilitated utilization of the protein by cells 
minimizing the undesired denaturation of FGF2 in the solution.  




1. Martin, P. Science 1997, 276, 75–81. 
2. Langer, R.; Vacanti, J.P. Science 1993, 260, 920-926. 
3. Caldwell, M.A.; Garcion, E.; terBorg, M.G.; He, X.; Svendsen, C.N. Exp. 
Neurol. 2004, 188, 408-420. 
4. Sommer, A.; Rifkin, D.B. J. Cell. Physiol. 1989, 138, 215-220. 
5. Tsuboi, R.; Rifkin, D.B. J. Exp. Med. 1990, 172, 245-251. 
6. Xu, R.H.; Peck, R.M.; Li, D.S.; Feng, X.; Ludwig, T.; Thomson, J.A. Nat. 
Methods 2005, 2, 185-190. 
7. Ribatti, D.; Vacca, A.; Rusnati, M.; Presta, M. Cytokine Growth F. R. 2007, 18, 
327–334. 
8. Ornitz, D. M. Bioessays. 2000, 22, 108–112. 
9. Werner, S.; Grose, R. Physiol. Rev. 2003, 83, 835–870. 
10. Partanen, J.; Vainikka, S.; Alitalo, K. Philos. Trans. R. Soc. Lond. B Biol. Sci. 
1993, 340, 297–303. 
11. Takayama, S.; Murakami, S.; Miki, Y.; Ikezawa, K.; Tasaka, S.; Terashima, A.; 
Asano, T.; Okada, H. J. Periodontal Res. 1997, 32, 667-675. 
12. Edelman, E.R.; Mathiowitz, E.; Langer, R.; Klagsbrun, M. Biomaterials 1991, 
12, 619-626. 
13. Jeon, O.; Ryu, S. H.; Chung, J. H.; Kim, B. S. J. Controlled Release 2005, 105, 
249-259. 
14. Wilcke, I.; Lohmeyer, J. A.; Liu, S.; Condurache, A.; Krüger, S.; Mailänder P.; 
 Chapter 4: Encapsulation of FGF2 
 101 
Machens, H. G. Langenbeck’s Arch. Surg. 2007, 392, 305-314. 
15. Liu, H.; Fan, H.; Cui, Y.; Chen, Y., Yao, K.; Goh, J. C. H. Biomacromolecules 
2007, 8, 1446-1455. 
16. Freeman, I.; Kedem, A.; Cohen, S. Biomaterials 2008, 29, 3260-3268. 
17. Donath, E.; Sukhorukov, G.B.; Caruso, F.; Davis, S.A.; Mohwald, H. Angew. 
Chem., Int. Ed. 1998, 37, 2202–2205. 
18. Sukhorukov, G.B.; Rogach, A.L.; Garstka, M.; Springer, S.; Parak, W.J.; 
Munoz-Javier, A.; Kreft, O.; Skirtach, A.G.; Susha, A.S.; Ramaye, Y.; Palankar, 
R.; Winterhalter, M. Small 2007, 3, 944-955. 
19. De Cock, L.J.; De Koker, S.; De Geest, B.G.; Grooten, J.; Vervaet, C.; Remon, 
J.P.; Sukhorukov, G.B.; Antipina, M.N. Angew. Chem. Int. Ed. 2010, 49, 6954-
6973. 
20. She, Z.; Antipina, M.N.; Li, J.; Sukhorukov, G.B. Biomacromolecules 2010, 11, 
1241- 1247. 
21. Antipov, A.A.; Sukhorukov, G.B.; Leporatti, S.; Radtchenko, I.L.; Donath, E.; 
Moehwald, H. Colloids Surf., A 2002, 198, 535–541. 
22. Dejugnat, C.; Halozan, D.; Sukhorukov, G.B. Macromol. Rapid Commun. 2005, 
26, 961-967. 
23. Antipina, M.N.; Kiryukhin, M.V.; Chong, K.; Low, H.Y.; Sukhorukov, G.B. 
Lab Chip 2009, 9, 1472-1475. 
24. Kozlovskaya, V.; Kharlampieva, E.; Mansfield, M.L.; Sukhishvili, S.A. Chem. 
Mater. 2006, 18, 328-326. 
25. Itoh, Y.; Matsusaki, M.; Kida, T.; Akashi, M. Biomacromolecules 2008, 9, 
2202-2206. 
 Chapter 4: Encapsulation of FGF2 
 102 
26. De Cock, L.J.; De Wever, O.; Van Vlierberghe, S.; Vanderleyden, E.; Dubruel, 
P.; De Vos, F.; Vervaet, C.; Remon, J.P.; De Geest, B.G. Soft Matter 2012, 8, 
1146-1154. 
27. Petrov, A.I.; Volodkin, D.V.; Sukhorukov, G.B. Biotechnol. Prog. 2005, 21, 
918-925. 
28. Volodkin, D.V.; Larionova, N.I.; Sukhorukov, G.B. Biomacromolecules 2004, 5, 
1962-1972. 
29. Volodkin, D.V.; Petrov, A.I.; Prevot, M.; Sukhorukov, G.B. Langmuir 2004, 20, 
3398-3406. 
30. De Koker, S.; De Geest, B.G.; Cuvelier, C.; Ferdinande, L.; Deckers, W.; 
Hennink, W.E.; De Smedt, S.; Mertens, N. Adv. Funct. Mater. 2007, 17, 3754-
3763. 
31. Biesheuvel, P.M.; Mauser, T.; Sukhorukov, G.B.; Moehwald, H. 
Macromolecules 2006, 39, 8480-8486. 
32. Cetin, M.; Aktas, Y.; Vural, I.; Capan, Y.; Dogan, L.A.; Duman, M.; Dalkara, T. 
Drug Deliv. 2007, 14, 525-529. 
33. Etheredge, L.; Kane, B.P.; Hassell, J.R. Invest. Ophthalmol. Vis. Sci. 2009, 50, 
3128-3136. 
34. Kapoor, M.; Nomiyama, T.; Bruemmer, D.; Kojima, F.; Crofford, L.J. Curr. 
Anaesth. Crit. Care 2006, 17, 13-20. 
35. Sobolewski, K.; Malkowski, A.; Bankowski, E.; Jaworski, S. Placenta 2005, 26, 
747-752. 
36. Chu, H.; Gao, J.; Chen, C.W.; Huard, J.; Wang, Y. Proc. Nat. Acad. Sci. USA 
2011, 108, 13444-13449. 
 Chapter 4: Encapsulation of FGF2 
 103 
37. De Koker, S.; De Cock, L. J.; Rivera-Gil, P.; Parak, W. J.; Auzély Velty, R.; 
Vervaet, C.; Remon, J. P.; Grooten, J.; De Geest, B. G. Adv. Drug Deliv. Rev. 
2011, 63, 748-761. 
38. Shchukin, D. G.; Shutava, T., Shchukina, E.; Sukhorukov, G. B.; Lvov, Y. M. 
Chem. Mater 2004, 16, 3446-3451. 
 
 Chapter 5: 5-FU Delivery 
 104 
 
CHAPTER 5 SYNERGISTIC EFFECT OF 
POLYELECTROLYTE-TiO2 NANOCOMPOSITES FOR 5-
FLUOROURACIL DELIVERY 
5.1 INTRODUCTION 
5.2. MATERIALS AND METHODS 
5.2.1 Materials 
5.2.2. Preparation of NCs with different surface chemistry 
5.2.3. Proton nuclear magnetic resonance (
1
H NMR) spectroscopy 
5.2.4. Morphology Measurement by SEM 
5.2.5. Transmission electron microscopy (TEM) 
5.2.6. Size and zeta-potential characterization 
5.2.7. Encapsulation efficiency (EE) and loading capacity (LC) measurement 
5.2.8. Cytotoxicity and 5-FU delivery with different carriers in vitro 
5.2.9. Cellular uptake ability evaluated by CLSM 
5.3 RESULTS AND DISCUSSION 
5.3.1. Preparation and Characterization of different NCs 
5.3.2. Cellular uptake of carriers 
 Chapter 5: 5-FU Delivery 
 105 
5.3.3. Anti-cancer effect of different carriers 
5.4. CONCLUSIONS 
5.5 REFERENCES 
 Chapter 5: 5-FU Delivery 
 106 
 
5.1 Introduction  
5-Fluorouracil (5-FU) is a widely used anti-cancer drug which shows anti-cancer 
effect to many solid tumors such as colorectal cancer, pancreatic cancer and breast 
cancer by inhibiting DNA synthesis in the S-phase of the cell cycle.
1-7
 However, 5-FU 
has very low localized accumulation and fast clearance in vivo and its therapeutic 
dose owns severe side effects like diarrhea, stomatitis, neutropenia and so on.
8-10
 
Intracellular drug delivery with proper carriers is a way to address those problems. 
Cheap and biocompatible titanium dioxide (TiO2) nanoparticle (NP) is a suitable 
carrier candidate.
11-18
 However, the TiO2 NPs have drawbacks like low loading 
capacity. Polymer-TiO2 nanocomposite (NC) is a good alternative which can be easily 
prepared by in situ photo-polymerization of vinylic monomers on the NP surface.
19
 
This method also changes the NP surface chemistry which affects its cellular transport 
pathway and cytotoxicity.
20,21 
The effect of the surface chemistry of NCs on 5-FU 
delivery is of great interest. Here we have prepared polyelectrolyte grafted TiO2 NCs 
with different surface chemistry and compared the 5-FU loading capacity of the TiO2 
NPs and NCs. We also evaluated the effect of the surface chemistry of the TiO2 NPs 
and NCs 5-FU delivery systems on cancer cell killing efficacy and side effect on non-
cancer cells. The surface chemistry of sulfonic group enhancing cancer cell killing 
synergistic effect is revealed. 
 
5.2. Materials and methods 
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5.2.1 Materials 
5-FU powder (≥99% ), tetramethylrhodamine isothiocyanate bovine serum 
albumin (TRITC-BSA), styrene sulfonate sodium salt (SS sodium salt or sodium 4-
vinylbenzenesulfonate, ≥90%), poly(styrene sulfonate) sodium salt (PSS, Mw. 77000), 
PAr, (Mw. > 70000), TiO2 photo-catalyst (P25, ~25nm nano-powder, ≥99.5%) and 
4’,6-diamidino-2-phenylindole dihydrochloride (DAPI) were purchased from Sigma-
Aldrich. 1X PBS buffer solution, FBS, PS, DMEM were purchased from Invitrogen. 
CellTiter 96
®
 AQueous non-radioactive cell proliferation assay (MTS) was purchased 
from Promega. MDA-MB231 breast cancer cell line and L929 fibroblasts were 
purchased from ATCC. DI water with specific resistivity higher than 18.2 MΩ·cm 
from a three-stage Milli-Q Plus 185 purification system was used in all experiments. 
 
5.2.2. Preparation of NCs with different surface chemistry 
1.0 mg of TiO2 NPs (P25) were added into SS aquatic solution (1.0 ml, 10.0 
wt.%) in a glass vial. After ultra-sonication and O2 removal by N2 bubbling, the glass 
vial was exposed to UV light (ELC-500 UV-visible light chamber system, 
30mW·cm-2 lamp at 365 nm) for 10 minutes to form the first NC with a -SO3
- 
exposed surface (TiO2/PSS). PAr was coated by mixing with TiO2/PSS for 10 min 
under sonication to introduce -NH3
+
 group to the surface (TiO2/PSS/PAr). All carriers 
were washed twice with DI water and then dried in vacuum oven overnight for weight 
measurement or resuspended in PBS buffer. 
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5.2.3. Proton nuclear magnetic resonance (
1
H NMR) spectroscopy 
1
H NMR spectra of the SS, PSS and TiO2/PSS particles suspension (all in D2O 
and 10 mg/ml) were recorded on a Bruker AV-400 NMR spectrometer at 400 MHz at 
room temperature. The 
1
H NMR measurements were carried out with an acquisition 
time of 3.2 s, a pulse repetition time of 2.0 s, a 30
o
 pulse width, 5208 Hz spectral 
width, and 32 K data points. To avoid the affect of pH values on the chemical shift of 
solvent peak, 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt was used as an 
internal standard and set at a chemical shift of 0 ppm. 
 
5.2.4. Morphology Measurement by SEM 
SEM measurement was performed on a Gemini Leo instrument operated at an 
acceleration voltage 5 kV. For sample preparation, a drop of TiO2 based sample 
suspension was applied to a conductive carbon film, dried overnight, and coated with 
gold. 
 
5.2.5. Transmission electron microscopy (TEM) 
TEM study was performed on a JEOL JEM-2010 system. The samples for 
TEM were prepared by adding 1 drop of TiO2 NPs or NCs suspension onto lacey 
carbon copper grids and dried at room temperature. 
 
5.2.6. Size and zeta-potential characterization 
The size and zeta potential of the NP and NC suspensions before and after 5-
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FU addition were analyzed by dynamic light scattering and laser Doppler micro-
electrophoresis method with the using of Zeta-sizer Nano ZS (Malvern Instruments, 
U.K.). 
 
5.2.7. EE, loading capacity (LC) and release of 5-FU 
10.0 mg of 5-FU was dissolved in 5.0 ml of PBS buffer to prepared 2.0 mg/ml 
of 5-FU stock solution. 100 l of 2.0 mg/ml the carrier suspension, 250 l of 2.0 
mg/ml 5-FU stock solution and 650 l of DI water were mixed together (the 
concentration of carriers in the final solution was 0.2 mg/ml and the concentration of 
5-FU was 0.5 mg/ml). The mixture was incubated in the dark place overnight at 4 
o
C. 
Concentration (conc.) of 5-FU in original 5-FU solution and the supernatants after 
overnight incubation with carrier was measured by UV absorption (267 nm). The EE 
was calculated as (Co-Ca)/Co*100%, where Co is the conc. of 5-FU in feeding 5-FU 
solution and Ca is the conc. of 5-FU in the supernatants after overnight incubation 
with carriers. And LC was calculated as (Mo-Ma)/Mc*100%, where Mo is the mass of 
5-FU in feeding 5-FU solution, Ma is the mass of 5-FU in the supernatants after 
overnight incubation with carriers and Mc is the mass of the carrier. After incubation, 
supernates were removed. The carriers were washed twice with DI water and 5-FU 
conc. in the supernates was measured by UV absorption. Then carriers were 
resuspended in PBS buffer and incubated in water bath at 37
o
C. The conc. of 5-FU in 
PBS supernates was measured at 0.5 h, 1 h, 2 h, 3 h and 24 h. 
 
5.2.8. Cytotoxicity and 5-FU delivery with different carriers in vitro 
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MB231 cells and L929 cells were seeded into 96-well plate (10000 cells/well) 
in 100 l of DMEM medium supplemented with 10% FBS and PS (50U/ml & 
0.05mg/ml) at 37 
o
C with 5% CO2 in a 95% humidified incubator at the first day. The 
mixture of test materials (2 g/ml) and 5-FU (5 g/ml, diluted with DMEM), and 5 
and 50 g/ml of free 5-FU were added at the second day. The cytotoxicity of free 5 
g/ml of 5-FU was used as a reference group. The 50 g/ml of 5-FU added group was 
used for comparison as well. Cell viabilities were measured by MTS assay after 1 day 
or 2 days incubation. 
 
5.2.9. Cellular uptake ability evaluated by CLSM 
TRITC-BSA (0.5 mg/ml) and its mixture with different carriers (0.2 mg/ml) 
were added to MB231 cells seeded glass base dishes. The cells were washed twice 
with DPBS buffer after one day incubation to remove free carriers that were not 
internalized by the cells. Then the cells were fixed in 4% paraformaldehyde for 15 
minutes and cell nuclear were stained with DAPI for 5 minutes before CLSM 
measurements. Images were obtained on a FV-1000 (Olympus) CLSM system 
equipped with a C-Apochromat 63X/1.2 Water Lens objective. The excitation 
wavelength λex = 543 nm and emission wavelength λem = 560 nm were used for 
scanning of FITC-BSA, while λex = 405 nm and λem. = 430 nm were used for DAPI. 
Bright field images were also captured. 
 
5.3 Results and discussion 
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5.3.1. Preparation and Characterization of different NCs 
The preparation of sulfonic acid group exposed NCs was based on a simple in 
situ photo-polymerization process (Figure 5.1a). SS was grafted onto the TiO2 NPs to 
form PSS grafted NCs (TiO2/PSS). Certain changes of the NPs proved the successful 
formation of polymer-TiO2 NCs. Firstly, the weight of the NCs had increased around 
5 times over the feeding initiator NPs. Then images from scanning electron 
microscopy (SEM) and TEM showed morphology changes and formation of 
amorphous polymer zone alone the edge of the TiO2 crystal structure (boundary was 
indicated by the arrow and red line in Figure 5.1b). Similar TEM discernible, 
structural difference was also observed in polymer coated TiO2 NCs by Thevenot et 
al.
20
 Results from dynamic light scattering (DLS) method showed that the size of NPs 
in water was less than 100 nm and its zeta potential was nearly neutral (Table 5.1). 
The size of TiO2/PSS NCs increased to over 200 nm and the zeta potential became 
highly negative due to the sulfonic acid group. 
1
H NMR spectroscopic results showed 
NCs formation as well (Figure 5.1c). Although NCs were not soluble in the solvent, 
the partially dissolved or hydrolyzed PEL chains still gave weak signals. By 
comparing their results, we found that the C-C bond connected H atom with a 
chemical shift less than 5 ppm only existed in PSS and the PSS grafted NCs 
(highlighted with cycles in Figure 5.1c). This result means that the initiator has 
converted C=C bond into C-C bond after UV exposure which indicates a successful 
polymerization. Oppositely charged PAr was used to coat the surface of TiO2/PSS 
NCs to form TiO2/PSS/PAr NCs as PAr could form ionic complex with PSS. After 
coating, small size increase and reversal of surface charge were observed. After 
overnight incubating with 5-FU, all carriers had further size increase and their zeta 
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potential values turned to be around -20 mV (Table 5.1). The slightly negatively zeta 
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corresponding SEM images of different carriers: TiO2 (left), TiO2/PSS (middle) and 
TiO2/PSS/PAr (right), scale-bars: 1m. (b) TEM images of TiO2/PSS NCs, scale-bar: 
5nm. (c) 1H NMR spectra of PSS, SS and TiO2/PSS NCs. Chemical shifts less than 5 
ppm were marked by cycles. 
 









 Size represented diameter here. 
 
5.3.2. Loading and release of 5-FU by carriers, and cellular uptake of carriers 
UV spectrophotometer was used to measure the 5-FU EE, LC and release. The 
result showed that the EE and LC of both NCs were twice higher than that of NPs 
(Table 5.2). But no apparent difference in EE and LC was observed between two NCs, 
which indicates the surface chemistry did not affect the 5-FU loading. The result from 
5-FU release experiment (Table 5.2) showed that the loading of 5-FU by all carriers 
was possibly due to simple adsorption, because more than 99% of the loaded 5-FU 
was released immediately at DI water washing steps. The remaining 5-FU was 
released within 0.5 h in PBS medium at 37
o
C. In the following in vitro 5-FU delivery 













TiO2 68 ± 10 -9.0 ± 4.0 175 ± 56 -22.3 ± 3.2 
TiO2/PSS 238 ± 33 -35.2 ± 3.6 840 ± 186 -17.6 ± 5.0 
TiO2/PSS/PAr 307 ± 30 29.8 ± 6.5 686 ± 106 -19.5 ± 3.7 
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experiments, carriers would be co-incubated with 5-FU solution without washing or 
separation. Since the loaded 5-FU could be released from all carriers, different anti-
cancer efficacy of carriers would not be related with the release property. TRITC-
BSA were loaded into carriers to study the cellular uptake ability of different carriers 
by MDA-MB231 breast cancer cells. The results showed that all carriers can be 
internalized by cells (Figure 5.2). But cells incubated with NCs showed higher 
intracellular fluorescent intensity than that with NPs and the control group. 
 








 No further 5-FU release was observed at following 1 h, 2 h, 3 h, 24 h intervals. 
 












TiO2 3.6 ± 1.6 9.0 ± 4.0 > 99.0 100.0 
TiO2/PSS 9.2 ± 1.4 23.0 ± 3.5 > 99.0 100.0 
TiO2/PSS/PAr 9.6 ± 2.2 24.0 ± 5.5 > 99.0 100.0 
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Figure 5.2. Cellular uptake of TRITC-BSA loaded carriers and the control group 
(TRITC-BSA only). The intensity profiles of red fluorescence along yellow lines and 
bright field images were listed below. Cell nuclei were stained with DAPI, scale-bars: 
10 m. 
 
5.3.3. Anti-cancer effect of different carriers 
5-FU delivery with TiO2 NPs and NCs and corresponding cytotoxicity assay 
were carried out in both MB231 cells and L929 fibroblasts. Although TiO2/PSS and 
TiO2/PSS/PAr had similar LC and cellular uptake ability, TiO2/PSS added with 5 
g/ml 5-FU group resulted in the lowest cell viability (Figure 5.3a). It was 
significantly lower than that of the 5 g/ml 5-FU reference group without carrier 
added, and even lower than or comparable to the 50 g/ml 5-FU group. Interestingly, 
although TiO2/PSS/PAr NCs were coated two layers of polymers, the enhanced 
cancer cell killing efficacy was similar to that of TiO2 NPs. The same trends 
 Chapter 5: 5-FU Delivery 
 116 
continued at day 2, and the enhanced cancer cell killing efficacy of the three carriers 
with 5 g/ml 5-FU groups became more significant (Figure 5.3b). Meanwhile, all 
pure carriers had negligible cytotoxicity when 5-FU was absent. So, the enhanced 
cancer cell killing efficacy (synergistic effect) in TiO2/PSS group was not directly 
caused by its own cytotoxicity, LC, or cellular uptake ability. Moreover, 5-FU release 
results (Table 5.2) showed that 5-FU could be released from all carriers at very fast 
speed, although the release is not a sustainable style. This indicated the synergistic 
effect was not due to different 5-FU release rates or 5-FU cannot be released from 
carriers. Most likely, the difference in surface chemistry of the three carriers was the 
reason for TiO2/PSS being the most efficient one to deliver 5-FU and result in a 
synergistic effect in killing cancer cells. It is also very important to note that such 
enhanced cell killing effect did not exist in non-cancer L929 cells. As shown in Figure 
5.3, the cytotoxicity of carrier alone groups was negligible after incubation with L929 
cells for 1 day or 2 days duration, and the cell viability of 5-FU loaded carrier groups 
was not significant lower than that of 5-FU alone group after 1 day or 2 days. This 
result shows the potential of using the TiO2/PSS NCs for targeting delivery. 
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Figure 5.3. Delivery of 5-FU by different carriers to MB231 cells and L929 cells 
compared with free 5-FU groups after 1 day (a) and 2 days (b) incubation (n=3, *: 
P<0.05, significant different from the reference group, free 5-FU at 5 g/ml).  
 
5.4. Conclusions 
In summary, TiO2/PEL NCs were demonstrated to have higher LC of 5-FU 
than that of TiO2 NPs. Both TiO2 NPs and NCs could be effectively internalized by 
MB231 cells. Among all three carriers, TiO2/PSS NCs with PSS surface coating 
showed most effective synergistic enhancement for 5-FU anti-cancer efficacy, while 
such enhancement did not show in non-cancer L929 cells. The surface coating of the 
TiO2/PSS NCs could be the most important factor, although the cellular uptake of the 
carriers could also enhance the cancer cells killing efficacy of 5-FU. Although TiO2 is 
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biocompatible, it may not be the most ideal carrier for drug delivery as it is not 
biodegradable and its accumulation in body may have side effects. In this study, we 
still used TiO2 nanoparticles for 5-FU delivery because its photo-activity allows 
simple surface modification and then we can easily prove the importance of PEL 
based surface engineering in designing drug carriers by comparing the anti-cancer 
efficacy of TiO2 NPs and NCs. 
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PELs such as Dex, PAr, Alg and PSS have been used for two purposes in this 
research: as shell materials of microcapsules and as surface modification materials of 
NCs. When biodegradable PEL complexes Dex/PAr and Alg/PAr composed 
microcapsules were used for encapsulation and release of a model protein TRITC-
BSA in chapter 3, it was found that Alg/PAr microcapsules can encapsulate higher 
amounts of TRITC-BSA and release at a slower rate compared with that of Dex/PAr 
microcapsules under the same environmental conditions. There may be two possible 
reasons behind this phenomenon. Firstly, Alg may form denser shells as its weakly 
charged carboxylic groups have been cross-linked by Ca
2+
 ions during dissolution of 
CaCO3 cores. Secondly, the carboxylic group usually shows higher affinity to proteins 
than that of the sulfate group which slows down the desorption of protein from the 
surface of Alg based microcapsules.
1,2
 It was also found that shell thickness, protein 
loading routine, volume of the surrounding medium and frequency of medium 
refreshment affected protein accumulation in the shell and subsequently changed the 
permeability of microcapsules.  
In chapter 4, Dex/PAr based PEL microcapsules prepared by the pre-loading 
routine were used to deliver the bioactive protein FGF2. PEL microcapsules showed 
very low cytotoxicity, good biocompatibility, high affinity to cell membrane, and 
abilities to be internalized and biodegraded by cells. Other advantages of using 
microcapsules included: higher EE compared to other carriers or routines, negligible 
bioactivity loss of FGF2 during the preparation procedure, the maintaining of 
 Chapter 6: Conclusions and Future Research 
 123 
bioactivity during FGF2 releasing from microcapsule from cell morphology change, 
enhanced cell proliferation and more effective FGF2 utility which was possibly 
because the attachment of microcapsules has shortened the release routine and then 
reduced the chance of degradation. 
When PELs were used for the surface modification of NPs in chapter 5, it was 
found that all TiO2/PEL NCs had higher drug loading capacity than NPs, while their 
cellular uptake ability did not demonstrate much difference. Our in vitro study on 
MB231 breast cancer cells and L929 fibroblasts demonstrated that the importance of a 
surface chemistry related synergistic effect: PSS grafted NCs could enhance the anti-
cancer efficacy of 5-FU most effectively. However, such an effect did not exist in 
normal cells L929 fibroblasts. In other words, this indicates the PEL based surface 
modification may have potential for targeting delivery application. 
 In summary, present research has enriched biomedical applications of PELs 
from the following aspects: advanced understanding on protein release mechanism 
which will allow tailoring of microcapsules design for different demands of release 
rate; the successful delivery of FGF2 by microcapsules in vitro is a good start to 
further in vivo study in wound healing and the discovery of a synergistic effect will 
facilitate the application of PEL surface engineering for enhanced cancer therapy. 
6.2 Future research 
With regard to the use of microcapsules for wound healing, the journey from a 
promising in vitro result to a commercially available product is still a long one. 
Alongside the FGF2, many other growth factors are also important to wound healing.
3
 
Thus, encapsulation of growth factors ‘cock-tail’ combinations could be a future area 
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of study. Subsequently, a series of studies on immunological and clinical responses 
are needed. 
Regarding the application of PEL for TiO2 surface modifications, many 
avenues of future research can be seen:  
1. The engineering of surface chemistry can be tailored for delivery of 
different targets. PELs with other dissociable groups like carboxylic acid groups, 
phosphate acid group or imines group can be screened for different purposes;  
2. PEL/TiO2 NCs also can play the role of a template for microcapsule 
preparation and its innate charges will facilitate LbL coating;  
3. Photo-sensitive TiO2 NPs can be embedded in the shell of microcapsules to 
enable the permeability tuning by UV irradiation;  
4. TiO2 NPs can be replaced by carbon doped TiO2 NPs as carbon doping can 
extend its photo-activity to visible light.
4-6
 Taking the possible damages of UV light to 
biological systems into consideration, the use of visible light will make the particles 
more suitable for various biomedical applications. From preliminary results of another 
project (data are not included in this thesis as they are not related with PELs), it was 
found that the carbon doping could also bring in a multi-color fluorescence property 
to the TiO2 NPs. Multi-color fluorescence means that the doped TiO2 NPs can emit 
red fluorescence under green light excitation, green fluorescence under blue light 
excitation and blue fluorescence under UV light excitation. Reasons behind multi-
color fluorescence emission are still not clear. But the spectrum looks very similar to 
the fluorescence from nitrogen-vacancy single quantum systems.
7,8
 The advantages of 
using these unique multi-channel fluorescent NPs and NCs as drug carriers may 
include the tracking of carrier location without adding extra fluorescent markers. But 
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efforts are still needed to improve the preparation method if we want the size 
distribution of particles to be very narrow in the nanometer range. 
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